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Abstract 
 
 Transgenic maize expressing the non-toxic B subunit of the Escherichia coli heat-
labile toxin (LT-B) in seed has proven to be an effective oral immunogen in mice.  Currently, 
there is considerable concern over accidental consumption of transgenic maize expressing 
LT-B by humans and domestic animals.  While consuming maize-expressed LT-B appears to 
have no toxic side effects, we have yet to define nonimmunogenic levels of transgenic LT-B 
when ingested. We also intend to determine if accidental exposure to LT-B could affect a 
later response to a vaccine containing LT-B as either an antigen or a carrier.  
 Our first goal was to determine the largest dose of LT-B orally administered in mice 
that does not result in a measurable immune response.  Mice were fed low doses of LT-B 
intermittently (days 0, 7 and 21) resembling vaccine dose scheduling. To determine the 
effects of previous exposure on vaccine administration, we fed mice intermittently or daily 
for 28 days to resemble two distinct inadvertent exposure scenarios.  We subsequently 
boosted all mice with vaccine-level doses of LT-B.  To determine immune responses, serum 
and fecal pellets were collected weekly for measurement of LT-B-specific antibodies. 
 Mice fed 0.02 µg LT-B intermittently demonstrated immune priming in 62.5% of the 
animals. Mice that were fed ≤ 0.002 µg LT-B showed no increase in specific antibody nor 
did they demonstrate immune priming, thus indicating that 0.002 µg LT-B was the highest 
nonimmunogenic dose tested.  Mice that were exposed to maize-derived LT-B, whether daily 
or intermittently, generate dose-dependent antibody responses to LT-B.  All animals that had 
been previously exposed to LT-B by either intermittent or daily feeding responded strongly 
to the vaccine-like booster doses, indicating that mice orally exposed to LT-B do not develop 
oral tolerance to LT-B.  Thus, inadvertent oral exposure to LT-B may not negatively impact 
future vaccinations containing LT-B as either an antigen or carrier. 
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Chapter 1:  Introduction and Literature Review 
 
Thesis Organization 
 This thesis consists of four major sections.  The first chapter includes a detailed 
review of the literature upon which the subsequent research is based.  The following two 
chapters consist of manuscripts prepared for submission to scientific journals that describe 
the research conducted and the results obtained.  The first manuscript has been published in 
the journal Environmental Health Perspectives (2007 Mar;115(3):354-60).  The second 
manuscript has been prepared for upcoming submission to Infection and Immunity.  The 
fourth chapter is a discussion of the findings from the research conducted as described in the 
previous two chapters. 
 
Literature Review 
I.  Vaccines 
A.  Introduction.  Development of vaccines is considered one of the most important 
public heath advancements of the 20th century.  With the development of childhood 
vaccination programs in the U.S., there has been a 90 to 100% decrease in death and disease 
caused by several formerly common childhood infections (Ogra et al. 2001).  In the last 50 
years alone, the U.S. has seen a 95 to 100% reduction in death and disease due to diphtheria, 
pertussis, tetanus, poliomyelitis, smallpox, measles, mumps, and rubella (Ogra et al. 2001).  
The advancements have lead to the worldwide eradication of smallpox and the near 
eradication of poliomyelitis.   
B. Vaccine routes and types.  The vast majority of vaccines currently licensed for use in 
the U.S. are parenterally injected and are composed of whole pathogens, either live-
attenuated or killed (inactivated), toxoids or purified capsular polysaccharides (Ogra et al. 
2001).  These vaccines have reduced or eliminated infections from the associated pathogens 
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and undoubtedly saved millions of lives.  However, the medical and scientific communities 
are beginning to see the limitations of parenteral vaccines and current research is now 
focusing on alternatives to parenteral delivery in order to facilitate vaccination programs in 
developing countries.   One of the problems associated with parenteral immunization is the 
use of needles, which in developed countries is viewed as unpleasant and something parents 
want their children to be able to avoid.  In developing countries, needles spread blood-borne 
diseases from person-to-person through their reuse due to short supply as well as through 
inadvertent needle sticks due to the inability to dispose of them properly (Levine 2003).   
 Alternatives to parenteral delivery that have been recently investigated include 
mucosal (most commonly through the oral or nasal routes) and transcutaneous 
administration.  Unlike parenteral immunization, which at best is only able to stimulate 
serum IgG and cell-mediated immunity (Goldsby et al. 2000), all three of these routes (oral, 
nasal and transcutaneous) have been shown to elicit both serum and mucosal antibody 
production in addition to stimulating cell-mediated immunity (Hammond et al. 2001; Levine 
2003; Poland et al. 2002).  Mucosal antibody, immunoglobulin A (IgA), production is 
especially important in preventing infection since most pathogens enter the body via mucosal 
surfaces.  All of these immunological benefits are gained while avoiding the use of needles.   
 In addition to changes in the route of administration, advancements in biotechnology 
have facilitated the development of vaccine types other than the traditional live-attenuated, 
inactivated, toxoid or polysaccharide types.  Early vaccines relied on culturing pathogens and 
then modifying or purifying components of them to be used in vaccines (Goldsby et al. 
2000).  Currently, genetic manipulation provides a means by which the genes for specific 
antigenic components can be expressed in safe vector systems and subsequently purified 
(Goldsby et al. 2000).  These systems include non-pathogenic bacterial, yeast, or mammalian 
cell cultures.  More recently these genes have also been expressed in edible plants to 
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facilitate oral vaccination without purification (Mason et al. 2002; Mercenier et al. 2001).  
Edible plants as oral vaccines will be the primary focus of this review. 
C. Mucosal immunity and oral tolerance.  In order to fully understand the benefits and 
drawbacks of oral immunization, an understanding of how the gut-associated lymphoid tissue 
(GALT) differs from systemic immunity is necessary.  The systemic immune system 
functions under normally sterile conditions and thus every foreign antigen is attacked swiftly; 
however, GALT is in constant contact with foreign antigens such as food proteins and 
commensal bacteria and thus needs to carefully select which antigens necessitate an immune 
response.  GALT is constantly down-regulating or suppressing effector cells so that 
excessive inflammation does not result from the constant exposure to foreign antigen 
(Holmgren and Czerkinsky 2005; Mayer 2000; Mestecky et al. 2005; Mowat 2005).  Because 
of these intrinsic differences, formulating antigen for an oral vaccine is more complex than 
that for non-mucosal vaccination and generally necessitates mixing your antigen of choice 
with a mucosal adjuvant (Mowat 2005; Ogra et al. 2001) or conjugating it to a carrier.  This 
adjuvant or carrier would direct the immune cells in the gut towards an immune response and 
away from suppression.   
 The typical immune response to oral antigen is described in a review by Mayer 
(2000) and is summarized briefly below.  It begins with the uptake of antigen from the lumen 
of the gut into specialized epithelial cells called M cells.  Antigen passes through the M cell 
and then is taken up by a macrophage or dendritic cell (DC). The DC or macrophage 
processes the antigen, travels to the underlying Peyer’s patch, and presents the antigen to 
lymphocytes inducing an active immune response (Gullberg and Soderholm 2006).  The 
cytokine microenvironment of the Peyer’s patch causes B cells to undergo class-switching 
towards an IgA isotype as well as to express homing receptors which direct these cells 
towards mucosal tissues.  Activated B cells then travel to the mesenteric lymph nodes, 
through intestinal lymphatics to the thoracic duct to the vena cava.  From here they circulate 
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in the blood and home to mucosal sites where they often end up in the lamina propria as 
terminally differentiated plasma cells which secrete IgA into mucosal surfaces. 
 Two unique features of the mucosal immune system are the common mucosal 
immune system (CMIS) and oral tolerance.  CMIS refers to the way all mucosal associated 
lymphoid tissues are interconnected due to the mucosal homing receptors expressed after 
activation (Holmgren and Czerkinsky 2005).  The specific mucosal tissues to which effector 
cells are likely to migrate is generally limited to a certain extent through 
compartmentalization.  For example, oral immunization is likely to induce antibody 
production not only in the gut, but also in the naso/oropharynx and mammary secretions 
(Holmgren and Czerkinsky 2005; Ogra et al. 2001).  While oral immunization is not strictly 
limited to antibody production in these two sites, these sites are more likely to secrete 
protective amounts of antibody.  Nasal immunization, on the other hand, is likely to induce 
antibody production in the lungs, naso/oropharynx and vagina (Holmgren and Czerkinsky 
2005; Ogra et al. 2001).  Thus, determining the best route of immunization is dependent upon 
which organ system most needs protective antibody.   
 Oral tolerance is a phenomenon of the mucosal immune system and refers to the state 
of systemic tolerance that results from previous oral administration of antigen. Oral tolerance 
was first described by Wells (1911) who orally administered an egg protein to guinea pigs 
and was unable to elicit an immune response when he subsequently boostered them 
systemically by injection. Unlike an active mucosal immune response, the processes of oral 
tolerance have not been fully elucidated even though the phenomenon has been observed for 
decades. 
 From the research that has been performed to date, we are beginning to understand 
the underlying mechanisms of oral tolerance.  When administered orally, soluble antigens 
tend to induce tolerance more often than particulate antigens (Mayer 2000).  Intestinal 
epithelial cells (IECs) covering the lamina propria are suspected to play a larger role in oral 
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tolerance than M cells which cover the Peyer’s patch.  This is because IECs take up soluble 
antigen from the lumen whereas M cells typically sample only particulate antigens (Chehade 
and Mayer 2005; Mayer 2000; Mowat 2005). Rimoldi and Rescigno (2005) suggested that 
IECs provide the signals necessary to determine whether the response to antigen will be 
tolerance or active immunity.  Their research indicates that in the presence of bacteria, 
pathogenic or not, IECs produce CCL-20, a chemokine which recruits immature DCs 
(Rimoldi et al. 2004).  Of more importance is that in the presence of pathogenic bacteria, 
IECs also produce inflammatory mediators such as IL-8.  Only DCs that were exposed to the 
soluble inflammatory mediators such as IL-8 produced by IECs were activated (Rimoldi et 
al. 2004).  Moreover, previous research indicated that immature DCs constitutively migrate 
to peripheral lymphoid organs where they present antigen and induce tolerance (Steinman et 
al. 2003).  Therefore, they concluded that in a state of inflammation, DCs are activated 
before presenting antigen and induce active immunity, whereas without inflammatory 
signals, immature DCs present antigen and induce tolerance.  This is merely one pathway for 
the induction of tolerance, however, as T cells in the Peyer’s patch have also been implicated 
in oral tolerance (Mayer 2000). 
 DCs, however, are only mediators in the signaling process and do not actually carry 
out the effector processes of tolerance.  Regulatory T cells of various subsets have been 
identified as the cells that ensure active immunity is not carried out.  The currently known 
subsets and their suspected mechanisms of tolerance have been recently reviewed by Chihade 
and Mayer (2005) and will be discussed briefly below.  Three subsets of CD4+ T cells, all 
acting in an antigen-specific manner, have been identified as regulatory cells in the gut:  Th3 
cells, TR1 cells and CD4+CD25+ T cells.  Th3 cells produce transforming growth factor-β 
(TGF-β) in response to antigen. TGF-β, which has long been known to induce IgA isotype 
switching in B cells (Mayer 2000), has also been implicated in oral tolerance.  TR1 cells are 
suspected to induce tolerance mainly through secretion of IL-10.  In a mouse model, IL-10 
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was shown to suppress antigen-specific immune responses (Groux et al. 1997).  The presence 
of CD4+CD25+ regulatory T cells is clearly necessary for oral tolerance; however, the exact 
mechanisms for this tolerance are as yet uncertain.  One theory is that their expression of 
surface bound TGF-β leads to immunosuppression (Nakamura et al. 2001), although another 
study found that these cells could induce tolerance without TGF-β (Piccirillo et al. 2002) 
suggesting that these cells induce tolerance through multiple mechanisms. 
 In addition to CD4+ cells, other types of regulatory T cells have been identified that 
may play a role in oral tolerance.  CD8+ suppressor T cells respond to antigen presented by 
IECs, which can act as non-professional antigen presenting cells.  This appears to lead to 
suppression of local immune responses although the exact mechanism has not been 
determined (Bland and Warren 1986) and whether these cells actually play a role in oral 
tolerance remains controversial (Mowat 2004).  Another regulatory T cell is the natural killer 
1.1 T (NK-T) cell found in the liver.  Small amounts of antigen sometimes pass through 
IECs, enter circulation via capillaries and travel through the liver where antigen presumably 
comes in contact with NK-T cells (Chehade and Mayer 2005).  Although the exact 
mechanism of tolerance is unknown, it was demonstrated that animals depleted of these cells 
suffered from colonic inflammation (Trop et al. 1999).  
 Other than a state of inflammation, various other factors have been shown to affect 
oral tolerance induction and each of these will be discussed briefly.  The dose of the antigen 
administered orally appears to affect how tolerance is carried out.  High doses of antigen tend 
to result in clonal anergy or deletion of reactive lymphocytes whereas low doses result in 
suppression, mediated by activation of the regulatory cells listed above (Blanas and Heath 
1999; Chehade and Mayer 2005; Mayer 2000).  As mentioned earlier, soluble antigens are 
more likely to result in tolerance than particulate antigens.  In addition to these antigen-
related factors, several host-intrinsic factors also seem to affect oral tolerance.  Host genetics 
appear to play a role as certain inbred mouse strains appear to be more susceptible to food 
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allergy than others (Lamont et al. 1988) and humans with food allergies carry common 
specific HLA genes.  The normal flora of the host may also play a role, although mixed 
results have been reported.  Host age may also be a factor with neonates and infants 
demonstrating less oral tolerance than adults given the same treatment (Chehade and Mayer 
2005). 
 Oral tolerance, while being a challenge for the development of oral vaccines, has 
been studied recently as a means by which to treat or prevent the development of 
autoimmune diseases.  The theory is that feeding autoantigens will suppress the immune 
response that is causing disease symptoms.  Studies in animal models have demonstrated 
more promising results than those in humans (Arakawa et al. 1998b; Bergerot et al. 1997; 
Holmgren and Czerkinsky 2005; Ogra et al. 2001; Sai et al. 1996; Wardrop and Whitacre 
1999).  One problem may be that many animal studies have used oral tolerance as a means of 
preventing disease, whereas most human studies focus on treating an existing condition 
(Wardrop and Whitacre 1999).  Some studies indicate that inducing oral tolerance in a 
previously systemically primed system is much more difficult than in a naïve system, if not 
impossible (Leishman et al. 2000; Mestecky et al. 2005).  In addition, one study in mice 
demonstrated that oral administration of ovalbumin lead to the development of active 
immunity (Blanas and Heath 1999).  These data demonstrate that caution must be taken in 
using oral tolerance as a means of preventing or treating disease in humans as this could 
instead lead to the development or exacerbation of disease.  More information on the basic 
mechanisms of oral tolerance will likely be necessary in order to develop effective treatment 
protocols with reduced risk of disease development or exacerbation. 
D. Oral vaccines and mucosal adjuvants.  Despite that GALT tends towards tolerance to 
foreign antigen as opposed to active immunity, effective oral vaccines have been approved 
for human use and more are currently being developed.  As mentioned earlier, oral 
vaccination is highly desirable because the local IgA production that is elicited is able to 
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neutralize and eliminate antigen before infection is established.  Currently, the rotavirus 
vaccine, RotaTeq, is the only oral vaccine used routinely in the U.S. (CDC 2006).  RotaTeq 
was first licensed in February 2006 after extensive clinical trials demonstrated protection as 
well as lack of adverse side effects such as intussusception, which was a problem with a 
previous oral rotavirus vaccine (Parashar and Glass 2006).  Other oral vaccines approved, but 
not routinely used in the U.S., protect against polio (OPV), typhoid, and adenovirus.  OPV 
was developed in the 1960s and was a highly effective vaccine; however, rarely the live virus 
was associated with causing vaccine-associated paralytic poliomyelitis (CDC 2000).  Due to 
the fact that after decades of polio vaccination the only cause of polio in the U.S. was due to 
oral vaccination, the Advisory Committee on Immunization Practices (ACIP) recommended 
in 1997 that all future vaccinations were to use the parenteral, inactivated formulation (IPV) 
(CDC 2000).  Currently OPV is still in use in developing countries that still have outbreaks 
of wild type polio.  In these countries, the benefits of oral vaccination (local antibody 
response and shedding of attenuated virus to non-vaccinated individuals) outweigh the 
dangers (CDC 2000).  Three vaccine types that protect against typhoid are available, one of 
which is orally administered (CDC 1994).  Typhoid vaccination is not carried out regularly 
and is only recommended for travelers to regions with endemic typhoid, those in close 
contact with carriers of Salmonella enterica serovar Typhi, and laboratory personnel who 
frequently work with S. Typhi (CDC 1994).  The adenovirus vaccine is only available for 
vaccination of military populations (CDC 1991).  One commonality for all of these oral 
vaccine formulations is that they consist of live, attenuated bacteria or viruses. 
 While few oral vaccines are currently available, much research is focused on 
developing more.  This research is not only focusing on developing oral vaccines to protect 
against gastrointestinal pathogens such as Escherichia coli, Helicobacter pylori and Shigella 
species (Khan et al. 2007; Nystrom and Svennerholm 2007; Ranallo et al. 2007; Sack et al. 
2007; Weltzin et al. 2000) but also respiratory pathogens such as Haemophilus influenzae, 
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Streptococcus pneumoniae and the influenza virus (Foxwell et al. 2006; Lu et al. 2002; Seo 
et al. 2002), and urogenital pathogens such as the herpes simplex virus (Mohamedi et al. 
2001).  While most of these new formulations are either inactivated or subunit vaccines, they 
all contain an additional component to boost the response and/or target the antigens to the 
mucosal surface.  It is clear that the majority of oral vaccines need an adjuvant of some kind 
in order to elicit a strong mucosal immune response, especially if live organisms are not 
used.  
 As mentioned earlier, in order to avoid inducing oral tolerance, some sort of signal is 
necessary so that effector cells recognize the antigen as a potential threat.  All currently 
licensed oral vaccines contain live organisms in order to send this signal.  However, live 
attenuated organisms could potentially pose problems for vaccine development.  For 
example, colonization of the gut is typically necessary for a strong immune response; 
however, colonization is often linked with pathogenicity.  Any residual pathogenicity of a 
vaccine strain is unacceptable and could not be used in infants and immunosuppressed or 
immunocompromised individuals.  In addition, using live organisms runs the risk of genetic 
recombination within the gut which could cause reversion to virulence (Bouvet et al. 2002).   
 Because of these challenges to live oral vaccine formulations, much research is 
focused on using mucosal adjuvants or delivery systems in order to boost the immune 
response to poorly antigenic proteins.  Although none of these are currently approved for 
human use, those that have been shown to enhance oral immune response to antigens include 
non-bacteria-derived ISCOMs (immunostimulating complexes) and microspheres as well as 
bacteria-derived CpG motifs, monophosphoryl lipid A (MPL) and ADP-ribosylating bacterial 
toxins.   
 ISCOMs are spherical structures composed of glycosides which encapsulate antigen.  
They have been shown to improve active immunity to soluble antigens and may induce both 
humoral and cell-mediated responses (Ogra et al. 2001).  They are able to boost responses by 
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fusing with the membrane of epithelial cells releasing antigen directly into the cell (Goldsby 
et al. 2000).  Microspheres are composed of biodegradable poly (lactic/glycolic) acid (Poland 
et al. 2002).  Orally delivered microspheres have been detected in Peyer’s patches, 
mesenteric lymph nodes and the spleen indicating that both mucosal and systemic immune 
responses could be generated through oral delivery (Ogra et al. 2001). 
 CpG motifs are unmethylated dinucleotides (cytosine (C) and guanine (G) connected 
by a phosphate group (p)) within particular base sequences of DNA.  Because vertebrate 
DNA is typically methylated in these regions, these unmethylated portions of DNA are 
recognized as bacterial by toll-like receptor (TLR)-9, thus inducing the release of 
inflammatory cytokines (Holmgren et al. 2005).  The use of CpG motifs as oral adjuvants has 
demonstrated the generation of Th1 responses which would be beneficial for vaccines against 
intracellular pathogens and viruses (Freytag and Clements 2005; Holmgren et al. 2005).  
Monophosphoryl lipid A (MPL) is derived from the lipopolysaccharide (LPS) of Salmonella 
and is recognized by TLR-2 and TLR-4 to lead to an inflammatory response and active 
immunity (Freytag and Clements 2005). 
 Unlike the previously mentioned adjuvants, the ADP-ribosylating enterotoxins are 
able to both direct the response towards active immunity as well as deliver conjugated 
antigen to the mucosal surface via the specific binding of their B subunits.  These toxins 
include cholera toxin (CT) produced by Vibrio cholerae and heat-labile enterotoxin (LT) 
produced by some enterotoxigenic strains of E. coli. While they are the most potent mucosal 
adjuvants known, their inherent toxicity has limited their use.  Attempts to retain their 
adjuvanticity while reducing or eliminating toxicity included the development of several 
mutants.  These include recombinant production of their non-toxic B subunits (CT-B and LT-
B) as well as whole LT toxin mutants with reduced toxicity.  While CT-B has demonstrated 
potential as an oral adjuvant (Seo et al. 2002), LT-B has shown very weak oral adjuvanticity 
for urease (Plant et al. 2003) and no oral adjuvanticity for ovalbumin (Weltzin et al. 2000).  
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Because LT-B has shown little potential for use as an oral adjuvant, non-toxic mutants of LT 
have been created which have demonstrated potential for adjuvanticity (Dickinson and 
Clements 1995; Guillobel et al. 2000; Lu et al. 2002). 
E. Plant vaccines as oral vaccines.  Plants serving as factories for the production of 
recombinant vaccine antigens are currently an area of major interest.  Much attention has 
been focused on this area of research due to the many benefits of using plants to facilitate 
oral vaccination.  First, plants are much more cost effective in producing recombinant 
antigens than other systems (Streatfield et al. 2001; Tacket and Mason 1999).  Production 
could be easily scaled up for mass vaccination campaigns by simply increasing acreage and 
vaccines could even be produced locally in developing countries if the antigen is produced in 
a food crop and requires no further purification (Mason et al. 2002; Tacket 2005).  Second, 
plant cells offer protection to the antigen to increase stability at ambient temperature for 
storage and transport (Streatfield et al. 2001).  In addition, some plant cell walls may provide 
protection to the antigen as it passes through the harsh environment of the stomach 
(Chikwamba et al. 2003) optimizing the immune response.  Third, plants as vehicles for oral 
vaccines offer improved safety.  Besides avoiding the use of needles through oral delivery, 
there are no known human pathogens that also infect plants, eliminating the concern for 
potential infectious contamination (Streatfield et al. 2001; Tacket 2005). 
 Along with the many advantages associated with plants as oral vaccines come 
challenges for vaccine developers.  The major one is ensuring that a strong immune response 
is generated against the vaccine antigen while maintaining tolerance to the food proteins 
surrounding the antigen (Tacket and Mason 1999).  Additionally, many antigens may require 
the addition of a mucosal adjuvant for the generation of an optimal immune response making 
tolerance to the food proteins even more difficult to maintain.  Despite this hurdle, several 
plant-based oral vaccines are under development and some have even progressed to human 
clinical trials, as discussed below.   
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 Many different plant-produced oral vaccines have been developed.  Nearly all of 
them have been tested in animals and many of them have proven to be protective against 
challenge.   Because of the route of entry of the pathogen, it makes sense to use oral 
vaccination to protect against gastrointestinal illness.  Vaccines have been developed against 
diseases caused by V. cholerae, E. coli, rotavirus and the porcine pathogen transmissible 
gastroenteritis virus (TGEV) (Arakawa et al. 1998a; Joensuu et al. 2006; Streatfield et al. 
2001; Wen et al. 2006; Yu and Langridge 2001).  In addition, plant-based oral vaccines to 
non-gastrointestinal illnesses have also been developed.  These include vaccines against 
Hepatitis B (reviewed in Kumar et al. 2007), HIV, measles, Severe Acute Respiratory 
Syndrome (SARS), tetanus, and tuberculosis (Huang et al. 2001; Li et al. 2006; Rigano et al. 
2006; Shchelkunov et al. 2006; Tregoning et al. 2005; Webster et al. 2002)).  Some of these 
vaccines were produced in tobacco or Arabidopsis, which may result in high antigen yields, 
but typically require purification of the vaccine antigen before oral delivery; however, many 
vaccines were developed in food plants such as potato, barley, lettuce, carrot, banana, cherry 
tomatillo, tomato and maize. 
 While many plant-based oral vaccines have been developed, only a half dozen have 
progressed to human clinical trials.  These include the E. coli heat-labile toxin B subunit (LT-
B) expressed in both potatoes and maize (Tacket et al. 1998; Tacket et al. 2004).  Both of 
these vaccines resulted in good serum IgG responses (90% and 78% of vaccinees, 
respectively); however, they demonstrated only moderate mucosal IgA responses (50% and 
44% of vaccinees, respectively).  Other vaccines have been developed to protect against 
Hepatitis B.  Those tested in humans were produced in lettuce and potato (Kapusta et al. 
1999; Thanavala et al. 2005) and while these vaccine formulations are distinct, they had 
similar effects on antibody responses (66% and 62% of individuals responded, respectively). 
A vaccine antigen expressed in spinach to protect against rabies resulted in 55% of 
volunteers having a significant increase in antibody (Yusibov et al. 2002).  While most of 
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these previous vaccines resulted in poor immune responses, a vaccine expressed in potatoes 
to protect against Norwalk virus demonstrated much better effects with 95% of volunteers 
developing significant increases in IgA antibody secreting cells; however, only 20% resulted 
in significant serum IgG titers and 30% for fecal IgA titers (Tacket et al. 2000).   
 While the results from human trials thus far have not demonstrated highly effective 
vaccines, they do stress that antigen-specific immune responses can be elicited in humans 
from the consumption of transgenic food products.  It is likely that in order to obtain optimal 
immune responses it may be necessary to modify the vaccination protocol in regard to the 
timing and dose, the particular plant within which the antigen is expressed and administration 
with buffers and/or addition of mucosal adjuvants. 
II. Model Antigen System 
A. Introduction.  During the development of new vaccine delivery systems, a model 
antigen is necessary for optimization of the new techniques.  Cholera toxin (CT) and the E. 
coli heat labile toxin (LT) and their non-toxic derivatives have been used as model antigens 
for developing effective mucosal immunization strategies. 
 Enterotoxigenic E. coli (ETEC) is a major cause of diarrheal disease throughout the 
world, but especially in developing countries where sanitation and clean water are limited.  
The two populations that are most greatly affected by ETEC are children under 5 years old 
who live in developing countries as well as travelers (of any age) to these countries (Qadri et 
al. 2005; Spangler 1992).  The World Health Organization (WHO) estimates that ETEC is 
the cause of 210 million cases of diarrhea and 380,000 deaths every year (WHO 1999).  The 
diarrhea associated with infection is primarily caused by two toxins produced by ETEC:  the 
non-antigenic heat-stable toxin (ST) and the highly immunogenic heat-labile toxin (LT) 
(Spangler 1992).  Because a component of LT has been the focus of my work, the remainder 
of this literature review will focus on LT and its B subunit (LT-B). 
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B. Escherichia coli heat-labile toxin.  LT is a member of the A-B toxin family (Rappuoli 
et al. 1999).  Other toxins in this family include cholera toxin, pertussis toxin, diphtheria 
toxin, Pseudomonas exotoxin A, Shiga toxin, shiga-like toxins, tetanus toxin, several 
botulinum toxins, and anthrax toxin (Spangler 1992).  These toxins consist of an 
enzymatically active A subunit and a non-toxic B subunit (Rappuoli et al. 1999).  Of the 
toxins in this family, LT is closely related to the cholera toxin (CT), with which it shares 
approximately 80% nucleotide sequence homology, similar three dimensional structures, 
binding specificities and modes of action (Rappuoli et al. 1999; Spangler 1992)).  LT is a 
heterohexameric protein consisting of one A subunit and a B subunit composed of five 
identical B monomers which bind to one another in a circular doughnut-like shape with an 
empty center (Fan et al. 2004).  The A subunit of LT consists of two domains:  A1 and A2 
(Spangler 1992).  LT-A1 is enzymatically active and is connected to LT-A2 through a 
disulfide bond (Spangler 1992).  LT-A2 serves to connect LTA1 to LT-B by inserting into 
the center hole of LT-B (Fan et al. 2004; Spangler 1992).   
 The mechanism of action of LT is highly complex and has been reviewed by Spangler 
(1992) and Rappuoli (1999) and is briefly discussed below.  LT-B facilitates toxin entry into 
intestinal epithelial cells by binding to the nearly ubiquitously expressed GM1 gangliosides.  
Each B subunit binds an individual GM1 ganglioside for a total of five bound gangliosides 
per LT-B molecule; however, only two B subunits are required for binding to GM1 
gangliosides (Rigano et al. 2003).  Upon LT-B binding, LT enters the cell in vesicles and is 
transported to the golgi where the A and B subunits dissociate.  The B subunit is later 
degraded.  The A subunit is transferred to the endoplasmic reticulum and then released to the 
cytosol.  At some point during transport, A1 and A2 are separated via proteolytic cleavage 
and disulfide bond reduction.  At this point, A1 is able to bind an adenosine diphosphate 
(ADP) ribosylation factor (ARF) which activates A1.  Upon activation, A1-ARF can bind 
nicotinamide adenine dinucleotide (NAD) and subsequently transfer an ADP ribose (ADPR) 
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from NAD to Gsα, the GTP-binding protein that regulates adenylate cyclase.  This Gsα-
ADPR then binds to guanosine triphosphate (GTP) and complexes with adenylate cyclase, 
which converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP).  
Because of the bound ADPR, GTP hydrolysis is prevented and adenylate cyclase remains 
activated resulting in abnormally high levels of cAMP and the release of salt and water into 
the lumen of the gut.  
 Despite the high toxicity of LT, this toxin has been evaluated for use in vaccines.  Its 
unusually high mucosal immunogenicity and adjuvanticity have prompted research that 
focuses on reducing or eliminating toxicity while maintaining immunogenicity and/or 
adjuvanticity.  As mentioned previously, strategies have focused on retaining the whole LT 
molecule, but using point mutations to eliminate toxicity either by preventing protease 
cleavage between A1 and A2 (Dickinson and Clements 1995; Guillobel et al. 2000; Lu et al. 
2002) or by mutations within the active site which prevent substrate (NAD) binding (Ryan et 
al. 2000; Tierney et al. 2003). Certain mutations result in complete loss of toxicity while 
others result in reduced toxicity and these mutants demonstrate immunogenicity as well as 
adjuvanticity.  Other strategies thus far have focused on recombinantly producing the non-
toxic B subunit alone which has proven to be highly immunogenic due to its receptor binding 
capabilities (Chikwamba et al. 2002a; Guidry et al. 1997; Lauterslager et al. 2001), although 
not necessarily functional as an adjuvant  (Plant et al. 2003; Weltzin et al. 2000).  LT-B may 
not be a successful oral adjuvant; however, because it binds specifically to intestinal 
epithelial cells it may serve as a successful carrier which would increase the immune 
response to an unrelated protein antigen if it were physically attached to LT-B. 
C. LT-B in vaccines.  Because of the great potential of LT-B as a vaccine component, 
several prototypic vaccines containing LT-B have been developed thus far using both plant 
and non-plant production systems.   
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 Recombinant LT-B not produced in plants is generally produced in bacterial or yeast 
production systems and subsequently purified before administration.  Several vaccines 
containing LT-B from a non-plant system will be briefly described below.  LT-B vaccines 
that have been used for potentially protecting against ETEC infection include an oral vaccine 
consisting of live-attenuated Salmonella Typhi expressing LT-B which resulted in 67% of 
human subjects responding to vaccination (Khan et al. 2007).  In addition, an oral vaccine 
composed of yeast-derived LT-B was shown to be immunogenic in chickens (Fingerut et al. 
2005).  In this same study, they produced a fusion protein consisting of LT-B fused to VP2, a 
viral protein from infectious bursal disease virus.  They demonstrated that LT-B served as an 
effective carrier molecule boosting the response to the viral antigen when administered orally 
in chickens. One study found LT-B to be an effective oral adjuvant for a different chicken 
vaccine (Fingerut et al. 2006).  This vaccine was composed of bacterially-produced LT-B co-
administered with rKnob, a recombinantly produced antigen from egg drop syndrome 
adenovirus, and demonstrated increased antibody production over animals given rKnob 
alone. Other non-plant-derived LT-B vaccines have used LT-B as an adjuvant or carrier for 
intranasal delivery of antigen.  Those demonstrating intranasal adjuvanticity in mice include 
a vaccine protecting against ocular herpes simplex virus type 1 (Richards et al. 2001) and 
influenza (de Haan et al. 1996).  LT-B has served as an effective carrier for intranasal 
vaccination in mice against prion proteins (Yamanaka et al. 2006) and Mycoplasma 
hyopneumoniae, a porcine pathogen (Conceicao et al. 2006). 
 A variety of different plant systems have been used for the expression of LT-B 
including both edible and non-edible plant species.  While non-edible plants such as tobacco 
generally require purification of the protein prior to vaccine administration to remove toxic 
compounds and improve palatability, purified LT-B has been shown to be immunogenic 
when administered intranasally, inducing high titers of serum IgG (Wagner et al. 2004).  
Arabidopsis has been used as an expression system for a fusion protein consisting of LT-B 
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fused to ESAT-6, a protective antigen of Mycobacterium tuberculosis (Rigano et al. 2006).  
An immune response was induced after oral administration in mice; however, it was not 
protective against challenge. 
 More commonly, LT-B has been expressed in edible plants that do not require 
purification and can be easily administered orally.  Early studies used potatoes as the 
expression system.  Potatoes transgenic for LT-B were shown to elicit serum and fecal 
antibodies following oral administration and partially protected mice against challenge with 
LT holotoxin (Mason et al. 1998).  The same research group then fed these potatoes to 
humans as a proof of concept that humans could elicit an immune response to antigens 
delivered in food (Tacket et al. 1998).  They found that 91% of volunteers demonstrated 
elevated titers for serum IgG, 55% for serum IgA and 50% for fecal IgA.  Another study of 
orally administered potato expressing LT-B demonstrated that mice did not respond unless 
they had been previously primed with the antigen extract subcutaneously (Lauterslager et al. 
2001).  Some of the problems associated with potatoes as an expression system include 
heterogeneous distribution of the recombinant protein, and the need to administer the 
potatoes raw in order to avoid breaking down the antigen with heat, which is generally not 
palatable.  In addition, potatoes spoil quickly which would make vaccination throughout 
developing countries difficult. 
 Other food plants that have been less studied as LT-B expression systems include 
tomatoes, lettuce and soybeans.  Tomatoes were used to express LT-B fused to ZP3, a mouse 
immunocontraceptive epitope (Walmsley et al. 2003).  This protein was successfully 
produced, but was not tested for immunogenicity or effectiveness.  Lettuce also successfully 
expressed LT-B, but has not been tested for immunogenicity (Kim et al. 2007).  Soybeans 
were recently shown to effectively express LT-B and oral administration provided partial 
protection against challenge in mice (Moravec et al. 2007).   
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 Maize as a production system for oral LT-B vaccines shows much promise.  In 
addition to the studies conducted in our institution, which will be discussed in detail below, 
others have independently expressed LT-B in maize and found it to be highly immunogenic.  
Oral administration of LT-B in maize to mice elicited similar serum antibody responses and 
better fecal IgA responses than those elicited by purified LT-B (Streatfield et al. 2001).  This 
same study demonstrated that mice orally vaccinated with LT-B in maize were completely 
protected against challenge with LT.  In addition, maize-expressed LT-B has been tested in 
humans (Tacket et al. 2004).  Oral administration resulted in 78% of volunteers 
demonstrating significant increases in serum IgG and in IgG and IgA antibody-secreting cell 
numbers; however, only 44% of volunteers had significant serum and fecal IgA responses. 
D. LT-B expressed in maize.  Maize as a production system for vaccine antigens has 
several advantages over other plant systems.  Each plant produces a large number of seeds 
which eases scaling up for mass production (Chikwamba et al. 2002a).  In addition, antigen 
expressed in the seed is often stored in storage bodies which provide a stable environment 
with very little enzymatic activity before germination (Chikwamba et al. 2002a).  This 
enables long term seed storage at ambient temperature with minimal degradation of the 
vaccine antigen.  In addition, maize is a major ingredient in livestock feed and a staple food 
in many countries (Chikwamba et al. 2002a).  Unlike other plant production systems, 
extensive heating is not required for processing which reduces the chance of antigen 
denaturation (Chikwamba et al. 2002a). 
 Our research group has previously demonstrated the expression of LT-B in maize 
(Chikwamba et al. 2002b).  The DNA sequence was modified from bacterial LT-B in order 
to optimize expression in potato and maize (Chikwamba et al. 2002b).  A seed endosperm-
specific promoter, the γ-zein promoter, was used in order to focus expression in the edible 
portion of the plant (Chikwamba et al. 2002b).  Further studies demonstrated that the maize-
produced LT-B was able to form functional pentamers within the seed as demonstrated by 
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the ability to bind GM1 gangliosides in an enzyme-linked immunosorbant assay (ELISA) 
(Chikwamba et al. 2002a).  In addition, immunogold labeling and electron microscopy were 
used to show that the LT-B was localized to the starch granules of the endosperm 
(Chikwamba et al. 2003).  Maize-expressed LT-B is more stable than bacterial LT-B added 
to ground maize highlighting the protective ability of the plant cell.  It appears that LT-B 
expressed in maize is protected from denaturation due to high temperatures and digestive 
enzymes (Chikwamba et al. 2003).  This protection is likely to increase the amount of 
functional LT-B that reaches immune cells and possibly result in a slow release of antigen to 
prolong immune exposure, both of which are likely to enhance immune responses 
(Chikwamba et al. 2003).  
 The LT-B transgenic maize was also shown to be highly immunogenic when orally 
administered to mice in four doses each containing 10 µg LT-B (Chikwamba et al. 2002a).  
The same study demonstrated that maize-expressed LT-B induced stronger mucosal antibody 
responses than maize spiked with an equivalent amount of purified bacterially produced LT-
B.  Not surprisingly, the LT-B-specific antibodies were cross-reactive with the closely related 
CT-B, and these antibodies protected mice against challenge with both LT and CT holotoxins 
(Chikwamba et al. 2002a).  Further studies of maize-expressed LT-B investigated its 
immunogenicity when orally administered to young vs. aged mice (Karaman et al. 2006).  
Mice primed as young adults demonstrated good systemic and mucosal antibody responses 
after boosters as aged mice.  Aged mice that were naïve to LT-B developed less serum IgG, 
slightly less fecal IgA and increased serum IgA as compared to young mice (Karaman et al. 
2006).  This suggests that immune regulatory mechanisms change with age and possibly 
favor IgA responses over IgG.  However, in older mice, the high serum IgA and low fecal 
IgA levels may indicate that less IgA is being transported into mucosal secretions where it is 
needed (Karaman et al. 2006). 
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 Edible vaccines produced in plants have been shown to be immunogenic in both 
animals and humans.  Plant-produced vaccines show much promise and could facilitate 
economical vaccine production and distribution in developing countries where vaccination is 
currently difficult to carry out; however, more research is necessary to optimize protein 
expression and immune responses.  Because plant-produced vaccines are a new area of 
research, studies involving their safety are also required. 
III. Risk Assessment 
 Some characteristics of optimized plant vaccine delivery systems also necessitate 
strict regulations during production and in-depth safety studies before vaccine approval, such 
as high antigen expression levels, high antigen stability and mass production of the product 
economically in the field.   
 Inadvertent exposure to plant-derived pharmaceuticals (PDPs), including plant-
derived vaccine antigens, at any level is considered unacceptable and is avoided through 
strict guidelines that ensure that the PDP will be confined at all times.  However, because 
these plants are grown in the field and typically do not look different from their non-
transgenic counterparts, the possibility of human error leading to contamination of the food 
supply exists.  Plant expression systems for oral vaccine production have much potential for 
inducing protective antibodies at the mucosal surface and for making vaccination possible in 
developing countries; however, this is a new area of research and regulations regarding their 
safety and handling are still being developed.  Currently, assessing the risk of PDPs involves 
combining procedures put in place for assessing both transgenic plants that serve as food 
(such as Roundup Ready soybeans, Bt corn and Flavr Savr Tomatoes (Metcalfe et al. 2003)) 
and pharmaceuticals themselves.  The two primary categories that need to be assessed are 
potential exposure to and hazard of the PDP (Wolt et al. 2006).   
 Exposure to PDPs will need to be evaluated for each individual protein and the plant 
it is being produced in.  The amount of PDP a human is likely to be exposed to involves 
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several factors including 1) the protein expression levels in the consumable portion of the 
plant, 2) the amount of the transgenic plant product that contaminates the non-transgenic 
food supply, 3) the fraction of this contaminated product that is processed into a food 
product, 4) the amount of transgenic protein that survives processing and digestion, and 5) 
the amount of this contaminated food product that is consumed (Wolt et al. 2006).  A recent 
risk assessment of maize-derived LT-B suggests that at even the highest levels of predicted 
LT-B expression in maize, it is highly unlikely that a person would be exposed to more than 
a functional dose (the amount given in a vaccine dose) and that a more likely exposure 
scenario would result in very low exposure that is not likely to have any effects (Wolt et al. 
2006). 
 The hazard potential of a PDP is assessed in a similar fashion to transgenic food 
crops, with appropriate modifications as PDPs are likely to be consumed in much smaller 
quantities and with much less frequency than transgenic food crops, whether used 
therapeutically or ingested inadvertently.  The first analysis is to determine substantial 
equivalence of the PDP to its non-transgenic counterpart.  This includes comparing the 
composition of the transgenic plant to its non-transgenic equivalent in terms of nutrients, 
anti-nutrients, fatty acids and amino acids (Metcalfe et al. 2003).  This process has not yet 
been completed for maize transgenic for LT-B (Wolt et al. 2006).  Substantial equivalence 
also involves comparing plant-produced LT-B to bacterially produced LT-B (Metcalfe et al. 
2003).  This has been completed for LT-B activity and physical characteristics with no 
differences identified (Chikwamba et al. 2002a; Wolt et al. 2006).   
 The second analysis involves testing for protein safety, including allergenicity and 
toxicity (Metcalfe et al. 2003).  Testing for allergenicity is a complex process that evaluates 
whether a protein is similar to known allergens and thus likely to induce allergy.  First, the 
source of the protein is evaluated.  If the protein originated from a source known to be 
allergenic, testing immediately proceeds to in vitro and in vivo testing which will be 
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described below (Metcalfe et al. 2003).  If the source is not known to be allergenic, the 
protein’s amino acid sequence and protease stability are compared to those of known 
allergens.  If a protein has less than 50% homology it is not likely to be allergenic, but if it 
has more than 70% homology to a known allergen it is likely to be allergenic (Metcalfe et al. 
2003).  Maize-derived LT-B has been evaluated for sequence homology to known allergens 
and does not appear to be homologous to any known allergens (Wolt et al. 2006).  The 
protein is then subject to pepsin digestion assays determining how long the protein can resist 
degradation.  Known allergens survive digestion for 8-60 minutes, whereas most non-
allergens are degraded within 15 seconds (Metcalfe et al. 2003).  These tests have been 
carried out with maize-expressed LT-B; however the results are not straightforward.  LT-B in 
maize resists degradation for greater than 15 minutes, which could indicate allergenic 
potential. Purified bacterial LT-B, however, is degraded within 5 minutes indicating that it is 
not necessarily allergenic (Chikwamba et al. 2003).  LT-B in maize is likely able to resist 
degradation simply because of its encapsulation within the maize cells and not because of 
properties inherent to LT-B.  Proteins that demonstrate allergenic potential based upon these 
assays are then subjected to in vitro and in vivo testing (Metcalfe et al. 2003).  Unfortunately, 
there are no known animal models that serve as good indicators of predicting allergy 
(Metcalfe et al. 2003) and thus testing is conducted in humans.  In vitro tests determine 
whether pooled serum IgE from individuals allergic to related proteins binds to the protein of 
interest (Metcalfe et al. 2003).  In vivo testing includes a skin prick test (SPT) and/or a 
double-blind placebo-controlled challenge in humans (Metcalfe et al. 2003).  SPT determines 
whether scratching the protein into the skin of individuals allergic to related proteins will 
result in an allergic response.  The challenge is usually more informative, but is also much 
more dangerous with the rare possibility that challenge could lead to anaphylactic shock 
(Metcalfe et al. 2003).  None of the in vitro or in vivo tests have been carried out with maize-
produced LT-B.   
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 Testing for protein toxicity is typically conducted in animal models.  This testing has 
been carried out for maize-produced LT-B and no toxicity was observed (Wolt et al. 2006).  
In addition, LT-B in plants has been tested for immunogenicity in both animals and humans 
with no toxicity reported (Chikwamba et al. 2002a; Moravec et al. 2007; Tacket et al. 1998; 
Tacket et al. 2004). However, testing for toxicity with LT-B is much different than other 
proteins due to its strong immunogenicity which could lead to indirect toxicity (Wolt et al. 
2006).  Until we completely understand the effects of LT-B on the immune system, we may 
not be aware of indirect toxic effects of LT-B.  The research presented in the following 
chapters determines the effects of LT-B on the immune system to serve as baseline 
information for future studies on immunogenicity and possible toxicity.  It includes 
identifying a minimum dose for which an immune response can be expected, evaluating the 
immune effects of daily consumption of maize transgenic for LT-B, and determining whether 
inadvertent exposure affects subsequent immunizations with maize-produce LT-B. 
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Abstract 
Background: Transgenic maize, which produces the nontoxic B subunit of the Escherichia 
coli heat-labile toxin (LT-B) in seed, has proven to be an effective oral immunogen in mice. 
Currently, there is considerable concern over accidental consumption of transgenic maize 
expressing LT-B by humans and domestic animals. We have yet to define nonimmunogenic 
levels of transgenic LT-B when ingested.  
Objectives: Our goal in this study was to determine the highest dose of LT-B orally 
administered in mice that does not result in a measurable immune response. We defined an 
immune response as specific serum or mucosal IgG or IgA significantly greater than 
background after three feedings (0.0002–20 µg) or a priming response induced by the 
intermittent feeding.  
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Methods: We fed transgenic maize pellets on days 0, 7, 21, and 49 and collected serum and 
fecal samples weekly. Serum was analyzed for LT-B–specific IgG and IgA, and feces was 
analyzed for LT-B–specific IgA.  
Results: We observed a dose-dependent anti-LT-B antibody response with high specific 
antibody concentrations in groups fed high doses (0.2, 2, 20 µg) of LT-B maize. Mice fed 
0.02 µg LT-B demonstrated immune priming in 62.5% of the animals. Mice that were fed ≤ 
0.002 µg LT-B showed no increase in specific antibody nor did they demonstrate immune 
priming, indicating that 0.002 µg LT-B was the highest nonimmunogenic dose tested.  
Conclusion: Our results demonstrate that LT-B derived from transgenic maize is 
immunogenic at nanogram levels when orally administered to mice.  
 
Introduction 
Many pathogens enter the body via mucosal surfaces. To prevent infection via this route, a 
protective secretory IgA response is required. Traditional parenteral vaccines primarily 
induce IgM and IgG responses, whereas mucosal vaccination, for example via the nasal or 
oral route, is able to elicit both an IgG and a secretory IgA response. Recently, expression of 
vaccine antigens in plants has been explored as an approach to facilitate oral vaccination 
(Kong et al. 2001; Ma et al. 2003; Tacket et al. 2000; Webster et al. 2002).  
 Plant-based oral vaccines have several advantages over traditional parenteral 
vaccines. Their production is more economical and their delivery is safer, as needles and 
animal products are not used (Lauterslager et al. 2001; Streatfield et al. 2001). Plant cells also 
provide protection to the antigen during long-term storage, transport at ambient temperature, 
and as it passes through the harsh environment of the stomach (Chikwamba et al. 2003). 
Most important, plants do not carry pathogens that are harmful to humans and animals 
(Streatfield et al. 2001).  
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 Our work focuses on transgenic maize expressing the B subunit of the Escherichia 
coli heat-labile toxin (LT-B). Previous studies have shown that this maize is both 
immunogenic, eliciting the production of secretory IgA upon oral administration to mice, and 
protective against challenge with the holotoxin (LT) (Chikwamba et al. 2002). LT-B is 
expressed within the starch granules of the maize seed as demonstrated by Chikwamba et al. 
(2003). Because of this natural encapsulation, maize-expressed LT-B is protected against 
harsh environmental conditions including high temperatures and enzyme degradation, while 
purified recombinant LT-B is not (Chikwamba et al. 2003). In addition, the natural 
encapsulation in maize starch granules may provide better protection and stability than other 
plant-produced vaccines such as potato, tomato, or tobacco. This increased stability should 
lead to improved immunogenicity.  
 The enhanced stability of maize-expressed LT-B is highly desirable for oral vaccine 
production, storage, and effectiveness; however, LT-B and its stability are also a concern in 
regard to environmental contamination and/or accidental consumption by humans and 
domestic animals. Safety issues remain that must be addressed. The use of transgenic maize 
to produce a vaccine component opens the possibility for low-dose antigen exposure of 
workers involved in its production or of consumers should the product inadvertently occur in 
foods (Wolt et al. 2006). Low-dose exposures have implications for product efficacy, which 
we address in this article. Furthermore, as immunogenicity is highly sensitive, evidence of 
immunogenic effects at low doses helps to set the lower bound for subsequent considerations 
of dose-dependent allergenic potential. Thus, we must determine the minimum dose for 
which no immune stimulation occurs upon accidental consumption.  
 The work we present here focuses on determining the immunogenicity of maize 
transgenic for LT-B in an intermittent feeding schedule and identifying a maximum 
nonimmunostimulatory dose. We hypothesized that some low levels of LT-B could stimulate 
nondetectable levels of specific antibody but result in immune priming—an ability to induce 
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the production of memory B cells that can later respond to the same antigen and produce 
specific IgG or IgA. We defined immune priming as a 4-fold increase of antibody (IgG or 
IgA) over background after a 20-µg LT-B booster exposure (Tacket 2005; Tacket et al. 1998, 
2004). Because of the high degree of specificity and sensitivity of the immune response to 
the highly immunogenic LT-B, doses of maize-derived LT-B that do not prime or stimulate 
the immune response should be considered an environmentally safe threshold. 
 
Materials and Methods 
Preparation of maize pellets. Production of maize transgenic for LT-B (seeds from 4th-
generation transgenic plants) and preparation of the maize seed pellets were carried out as 
described previously (Chikwamba et al. 2002). The pellets were formed by combining 
appropriate amounts of ground transgenic maize seed with ground nontransgenic (nt) maize 
seed to ensure that each pellet was a consistent size and contained the amount of LT-B 
indicated for each group. For the second study, we prepared the lowest doses (0.0002–0.02 
µg LT-B) by mixing the ground transgenic maize seed with ground nt maize seed 1:300 to 
make a lower LT-B level transgenic mix. The total weight of maize seed in each pellet was 
0.811 g for the first study and 0.937 g for the second study. The ground maize seed for each 
pellet was mixed with 600–700 µL of phosphate-buffered saline (PBS) [1.9 mM NaH2PO4, 
8.1 mM Na2HPO4, 0.15 M NaCl (pH 7.3)], formed into a pellet, and air-dried overnight. 
Ground nt maize seed was used to make pellets of similar weight to feed to the negative 
control groups.  
 To ensure that LT-B content in the maize remained constant during pellet formation, 
one extra pellet was formed per dose per feeding for analysis of LT-B content using a 
ganglioside-dependent ELISA. Three to four pellets of each type were frozen until ELISA 
analysis of LT-B content (four samples from each pellet). We detected no significant 
differences between the intended amount and the amount measured with ELISA for all 
   38
pellets except the 20-µg pellets. The 20-µg pellets had higher amounts of LT-B than 
intended. These amounts ranged from 26.5–40.8 µg LT-B per pellet instead of 20 µg (p < 
0.0001; data not shown). Despite the range of measured LT-B in the 20-µg pellets, we will 
continue to refer to this dose as the nominal 20-µg dose and animals given that dose as the 
20-µg group.  
Oral immunization of mice. We obtained 4- to 6-week-old female BALB/c mice from 
Harlan Sprague Dawley (Indianapolis, IN, USA) and allowed them a 2-week acclimation 
period with a 12-hr reversed light/dark cycle before beginning the experiment with lights on 
at 2100 hr. The mice were housed four per cage in the Iowa State University (ISU) animal 
facility with food and water ad libitum. Animals were treated humanely, and all procedures 
were approved by the ISU Institutional Animal Care and Use Committee.  
 Before the maize seed pellets were fed to the mice, the mice were fasted overnight 
(during the light phase) with water ad libitum. While eating the pellets, mice were housed 
individually with water ad libitum and were allowed to eat the pellet for 4 hr or until the 
pellet was finished, typically a maximum of 6–8 hr for the slowest mice. Upon completion of 
the pellet, the mice were returned to group cages with mouse chow and water ad libitum.  
 In the first study, we divided mice into six groups of four mice each. The 
experimental groups were fed 0.02, 0.2, 2, or 20 µg LT-B per pellet per feeding. The two 
control groups were fed nt maize pellets. The maize pellets were fed on days 0, 7, and 21. To 
test for immune priming, on day 49 all mice were fed a 20-µg LT-B pellet, including one 
group previously fed nt maize (nt + 20). In addition, one nt group was fed nt maize pellets on 
day 49.  
 In the second study, we used the same experimental design except that some mice 
were fed lower doses of LT-B. The groups consisted of mice fed 0.0002, 0.002, 0.02, and 20 
µg LT-B per pellet per feeding and two groups fed nt maize. To test for immune priming, on 
day 49 the mice were all fed 20 µg LT-B, except one nt group. Thus, internal repeats of the 
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nt, nt + 20, 0.02-, and the 20-µg groups were included for a total of eight mice receiving each 
of these treatments over two experiments.  
Sample collection and preparation. We collected serum and fecal pellets before the initial 
dosing and weekly throughout both studies to detect LT-B–specific serum IgG and IgA 
concentrations and fecal IgA concentrations. Blood was collected via the saphenous vein, 
using heparinized capillary tubes and centrifuged with serum separator gel (Vacutainer Plus 
plastic serum tube; Becton Dickinson, Franklin Lakes, NJ, USA) at 6,000  g in a bench top 
microcentrifuge (Jouan M14.11; Thermo Electron Corp., Waltham, MA, USA) for 10 min. 
The serum was collected in microcentrifuge tubes and stored at –20°C until analyzed for LT-
B–specific IgG and IgA by ELISA as described below.  
 Fecal pellets were collected from each mouse, frozen, lyophilized, and stored at 
-20°C. We extracted lyophilized pellets by adding extraction buffer [0.05% NaN3, 10 µg/mL 
leupeptin (Sigma, St. Louis, MO, USA), 0.25 mM PefablocSC ( Sigma) in PBS] at 10 µL/mg 
of lyophilized feces, vortexing, and extracting overnight at 4°C. Before analysis, the samples 
were placed on a shaker (Tekmar VXR-S10; Janke & Kunkel, Staufen, Germany) at 1,000 
rpm for 90 min, then centrifuged at 6,000  g for 10 min with serum separator gel. The liquid 
extract was collected and analyzed by ELISA for LT-B–specific IgA as described below.  
Euthanization. Mice were euthanized on day 57 for the first study; for the second, half the 
mice were euthanized on day 55 and the other half on day 56. For both studies, mice were 
euthanized with CO2.  
Lung lavage. After mice were euthanized we performed lung lavages by exposing the 
trachea, inserting a TomCat catheter (Kendall Sovereign, Tyco Healthcare, Mansfield, MA, 
USA), and flushing the lungs twice with 0.8 mL sterile PBS. The samples were centrifuged at 
6,000  g for 10 min to remove cells and stored at –20°C until analysis for LT-B–specific IgA 
by ELISA as described below.  
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ELISAs. We performed ELISAs for LT-B– and LT-B–specific antibodies as previously 
described (Chikwamba et al. 2002; Karaman et al. 2006) unless otherwise noted. All mouse 
samples, which were analyzed individually, and reagents were added 50 µL/well, and 
between each step wells were washed 4 times with 100 µL/well PBST [0.05% Tween 20 
(polyoxyethylene sorbitan monolaurate; Sigma) in PBS].  
Detection of LT-B–specific IgG and IgA. Measurements of LT-B–specific IgG (serum 
samples) and IgA (serum, fecal, and lung lavage samples) were carried out as described 
previously (Karaman et al. 2006) with minor changes. Briefly, all fecal extracts were 
measured within 24 hr of extraction. Sample concentrations were determined by comparing 
to a standard curve consisting of wells coated with either purified mouse IgG (MOPC 21, 
Sigma) with a range of 1.37–1000 ng/mL or IgA (Bethyl Laboratories, Montgomery, TX, 
USA) with a range of 0.46–400 ng/mL. Samples were diluted appropriately to fall within the 
linear range of the curve. End point readings were taken at 405 nm using the EL 340 
microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) and data collected using 
KC Junior software (version 1.17, Bio-Tek Instruments, Inc.) using a four-parameter fit 
standard curve. Samples reading below the standard curve were reported as one-half the 
value of the lowest detectable standard to permit log transformation of the data for statistical 
analysis.  
Detection of LT-B in maize. We extracted LT-B from ground maize or crushed maize 
pellets equivalent to those used for feeding using a sodium phosphate extraction buffer 
[sodium phosphate buffer (pH 6.6) 25 mM; sodium chloride 100 mM; EDTA, 1 mM; Triton 
X-100, 0.1%] with protease inhibitors (leupeptin, 10 µg/mL; PefablocSC, 0.25 mM) at 10 
µL/mg maize. Samples were extracted with buffer shaking at 1,000 rpm at 37°C for 2 hr. The 
extract was collected by centrifuging at 6,000  g for 15 min in a bench top microcentrifuge.  
 We determined LT-B content of maize extract using a ganglioside-dependent ELISA 
as described previously (Chikwamba et al. 2002) with minor changes. LT-B was detected by 
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incubating with rabbit anti-LT-B antibody (diluted 1:10,000; Immunology Consultants 
Laboratory, Inc., Newberg, OR, USA), then incubating with biotin-conjugated goat anti-
rabbit IgG (diluted 1:5000; Sigma). The secondary antibodies were detected using 
streptavidin-horse radish peroxidase (diluted 1: 1000; Becton Dickinson), then incubating 
with ABTS (3-ethylbenzthiazoline-6-sulfonic acid; Sigma) substrate buffer [0.1 M citric acid, 
0.55 mM ABTS (pH 4.25)]. Values were determined by comparing to a standard curve of 
purified bacterial LT-B (provided by J. Clements).  
Statistical analysis. We analyzed the data with general analysis of variance, using LT-B 
dose and sample day as variables in the model. Because of unequal variance between the 
groups, the antibody data were log transformed before analysis (Kirk 1982). Each sample day 
that was significantly different (p < 0.05) from the prefeed date was further analyzed by 
between group contrasts for that day. Analysis was conducted using the statistical software 
Statistix (version 8; Analytical Software, Tallahassee, FL, USA). We used non-log-
transformed data for graphs. Immune responses were divided into two types and defined as 
follows: An antibody response is demonstrated by antibody concentrations significantly 
higher (p < 0.05) than those of the nt-fed group, and immune priming is demonstrated by 
antibody concentrations 4-fold higher than those of the nt-fed group 5–6 days after a 20-µg 
LT-B dose (Tacket 2005; Tacket et al. 1998, 2004).  
 
Results 
LT-B–induced dose-dependent response with immune priming. In our first experiment 
we tested the immunogenicity of various doses of LT-B from transgenic maize. To identify a 
nonimmunostimulatory dose, we tested 10-fold differences of LT-B doses (ranging from 0.02 
to 20 µg per feeding) using an intermittent feeding regimen previously shown to induce a 
robust antibody response in 28 days with pellets fed on days 0, 7, and 21 (Chikwamba et al. 
2002).  
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Serum IgG. Intermittent feeding of LT-B induced a dose-dependent serum IgG response 
(Figure 1A). Mice fed 20 µg LT-B had low serum IgG levels (0.318 ± 0.061 µg/mL) but 
these levels were significantly higher than those of mice fed nt maize (0.169 ± 0.018 µg/mL) 
by day 6 (p = 0.0035) and were significantly higher than all other groups on days 13–48 (p < 
0.05). Mice fed 2 and 0.2 µg LT-B had significantly higher concentrations of IgG by day 13 
compared with the nt group (p < 0.0001 for both groups on days 13–48). The concentrations 
of specific IgG in the 0.02-µg group were low, but demonstrated a significant increase on day 
27 (0.298 ± 0.039 µg/mL) compared with the nt group (0.159 ± 0.018 µg/mL) (p = 0.0038), 
with significance continuing through day 48 (p ≤ 0.0089).  
 The peak antibody concentration for all groups was reached on day 55, 6 days after 
the 20-µg booster as seen in Figure 1B. After the booster, LT-B–specific IgG levels were 
significantly increased for mice in the 20-, 2-, 0.2-, and 0.02-µg groups compared with the nt 
group (p ≤ 0.0065). All mice in the 20-, 2-, and 0.2-µg groups demonstrated antibody levels 
at least 4 times higher than nt mice on day 55. In the 0.02-µg group, two of four (50%) mice 
had antibody levels 4 times those of the nt control group, which is indicative of immune 
priming. There was no statistical difference between either of the nt groups for serum IgG 
throughout the study, even after feeding one group 20 µg LT-B on day 49 (p = 0.7085).  
Serum IgA. As with serum IgG, feeding LT-B generally induced a dose-dependent response 
in serum IgA (Figure 2A). Significantly increased antibody levels compared with those in the 
nt group were observed in the 20-, 2-, and 0.2-µg LT-B groups beginning on day 13 and 
continuing to the end of the study (p ≤ 0.0071) (Figure 2A,B). The 0.2-µg group 
demonstrated higher but not significantly different levels of antibody compared with the 2- 
and 20-µg groups on days 13 and 20. Additionally, the antibody serum IgA levels of 0.2-µg 
group remained higher than those of the 2-µg group until the end of study. Although we are 
not sure why the lower dose resulted in higher antibody levels, we are certain that it was not 
a technical error, as the same serum samples demonstrated a dose-dependent IgG response. 
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We hypothesized that perhaps a lower dose, such as 0.2 µg LT-B, is optimal for stimulating 
an early IgA response Also, the high average value was not just due to one outlier in the 0.2-
µg group, as on day 13, three of four mice in the 0.2-µg group had higher antibody levels 
than the mice in the 2-µg group for serum IgA.  
 Because of the short half-life of IgA, obtaining a high level of IgA antibody 
significantly different from that in the nt group was not always observed with consecutive 
sample dates. This was demonstrated by the 0.02-µg group, which was marginally different 
from the nt group (p = 0.0785) on day 13 and significantly different on days 27, 34, 48, and 
55 (p ≤ 0.0351). On day 55, three of four (75%) mice in the 0.02-µg LT-B group appeared to 
have responded to the 20-µg booster dose with LT-B–specific IgA levels 4 times higher than 
those of the nt control group (Figure 2B), suggesting that these three mice were 
immunologically primed. There was no significant difference between the nt and nt +20 
groups throughout the study (p = 0.9481 on day 55) and none of the mice (zero of four) in the 
nt + 20 group had antibody levels 4 times higher than those of the nt group on day 55. 
Because of a lack of samples, no data from day 6 of the study were obtained.  
Fecal IgA. Mucosal IgA was measured in extracts of lyophilized fecal material and 
expressed as micrograms per gram of fecal material as shown in Figure 3. Mice fed 20 µg 
LT-B had significantly higher levels of IgA in fecal material than those of the nt group on 
day 13 (p < 0.0001) and again on day 27 throughout the rest of the study (p ≤ 0.0019). The 2-
µg group had significantly higher levels than those of the nt group on days 13, 27, 34, 41, 
and 55 (p ≤ 0.0371). Similar to the serum IgA results, mice fed 0.2 µg LT-B had levels of 
fecal IgA that were significantly higher than those of the nt group by day 13 (p < 0.0001) and 
throughout the remaining sample dates (p ≤ 0.0384).  
 Fecal IgA levels were statistically higher in the 0.2 µg group than those in the 2 µg 
LT-B group on days 13, 20, and 55 (p < 0.05). Again, this was not because of an outlier in 
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the group, as on all those dates at least three of four mice in the 0.2-µg group had higher 
antibody levels than those of the mice in the 2-µg group.  
 Fecal antibody concentrations of mice fed 0.02 µg LT-B reached statistical 
significance on days 20, 27, 34, and 55 (p ≤ 0.0163) with antibody levels only marginally 
higher than the those of the nt group on days 41 and 48 (p = 0.0515 and 0.0712, 
respectively). On day 55, 1 week after the 20-µg booster, one mouse in the 0.02-µg group 
had 4 times the antibody concentration of that in the nt group (Figure 3B), suggesting that 
immune priming had occurred in one of four mice. The nt and nt + 20 groups were not 
statistically different throughout the study (p = 0.7278 on day 55).  
Confirmation of 0.02-µg threshold for immune priming. During the second intermittent 
feeding study, antibody responses to low doses of LT-B administered orally in transgenic 
maize were measured. Because our first study demonstrated a significant increase in antibody 
concentrations and immune priming in some mice fed 0.02 µg of LT-B, we chose to repeat 
this dose and test two doses, each 10-fold lower in order to identify a nonimmunogenic dose. 
We also included a 20-µg LT-B dose as a positive control. Thus, two groups were repeated 
from the first experiment and two groups were new. As in the first experiment, we looked for 
production of serum and fecal antibody as well as immune priming.  
Serum IgG. As seen in Figure 4A, mice fed 20 µg LT-B had significantly elevated levels of 
serum IgG (0.296 ± 0.035 µg/mL) by day 6 (p = 0.0046) compared with the nt group (0.201 
± 0.017 µg/mL) and had significantly higher levels throughout the study (p < 0.0001 for all 
remaining sample dates), reaching peak levels on day 54 that were similar to those observed 
in the first study (Figure 4B vs. Figure 1B). The 0.02-µg group had marginally higher levels 
than those of the nt group on days 27, 41, and 48 (p = 0.0535, 0.0594 and 0.0514, 
respectively) and significantly higher levels on days 34 and 54 (p = 0.0335 and 0.0257, 
respectively). No other groups had IgG concentrations significantly different from those of 
the nt group (Figure 4A,B). On day 54 for the 0.02-µg group, one of four (25%) animals 
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demonstrated an antibody level 4 times that of the nt group (4.2 µg/mL vs. 0.2 µg/mL), 
suggesting that immune priming had occurred in that animal (Figure 4B). Despite that one 
animal in the nt + 20 group demonstrated elevated antibody concentrations after the 20-µg 
LT-B booster, the increase may be the beginning of primary response because the level of 
antibody (1.4 µg/mL) is far below that of the primed mouse in the 0.02-µg group (4.2 
µg/mL). Additionally, the nt + 20 group was not statistically different from the nt group.  
Serum IgA. The serum IgA concentrations of the 20-µg LT-B group (0.5721 µg/mL) were 
significantly higher than those of the nt group (0.0607 µg/mL) by day 6 (p = 0.0088 on day 6 
and p < 0.0001 for all remaining sample dates), as seen in Figure 5A. The antibody 
concentrations of the 0.02-µg group were marginally different from those of the nt group on 
day 27 (p = 0.0548) and significantly different on day 34 and all subsequent days (p ≤ 
0.0294). No other group had antibody concentrations significantly different from those of the 
nt group throughout the study. Once again the 0.02-µg LT-B group had two of four (50%) 
mice that appeared to be primed (Figure 5B). To calculate the level of antibody 4 times 
higher than those of the nt group for this data set, we used the data from the nt + 20 group, as 
all mice in the nt group had no detectable antibody on day 54. No other group (0.0002 or 
0.002 µg) had responders by this standard.  
Fecal IgA. The 20 µg LT-B group had antibody concentrations marginally higher than those 
of the nt group by day 13 (p = 0.0574) and significantly higher by day 20 (p = 0.0046) and 
throughout the remainder of the study (p ≤ 0.0202), as seen in Figure 6A. The 0.02-µg LT-B 
group did not have a significant increase in antibody concentrations compared with those of 
the nt group; however, after the 20-µg booster, one of four (25%) mice responded with 4 
times the antibody concentrations of those of the nt group, suggesting immune priming 
(Figure 6B). No animals fed lower doses of LT-B responded by either measure.  
IgA from lung lavages. Mucosal IgA was measured in lung lavage fluid of euthanized mice 
(Figure 7). The 20- and 0.02-µg LT-B groups had significantly elevated levels of IgA 
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compared with those of the nt group and the negative control group, which was never fasted, 
handled, or fed maize pellets (p < 0.0001 and p = 0.0029, respectively).  
Frequency of immune priming with 0.02 µg LT-B. Although the fecal IgA measurements 
in the second study for the 0.02-µg group were not significantly higher than those of the nt 
group, this dose resulted in significant levels of antibody in all other measures for both 
studies at least at one sample day before the 20-µg booster as well as by day 54 or 55. 
Additionally, approximately half the mice in both studies were primed, based upon antibody 
levels at least 4-fold higher than those of the nt group. One mouse in each study 
demonstrated priming using all three measures (serum IgG, serum IgA, and fecal IgA), 
whereas all other mice responded in only one or two of the measures (Table 1). The rates of 
immune priming varied between different measures (serum IgG vs. serum IgA vs. fecal IgA), 
indicating that some are more sensitive than others. We found serum IgA to be the most 
sensitive, which is likely because oral exposure to an antigen primarily elicits an IgA 
response as opposed to IgG. Also, fecal IgA is difficult to measure accurately because of the 
high rate of antibody breakdown in the feces. Using our most sensitive measure, serum IgA, 
we observed that the overall rate of immune priming in mice fed 0.02 µg LT-B intermittently 
is 62.5%.  
Effect of maize consumption on mouse weight. Upon euthanization, the weight of each 
mouse was recorded. For both studies, we found no significant difference between mice fed 
transgenic maize compared with mice fed nt maize (p ≥ 0.14). In addition, for the second 
study, no significant difference was detected between mice that were handled, fasted, and fed 
transgenic or nt maize compared with mice that were never handled, fasted, or fed maize (p ≥ 
0.11), thereby demonstrating that the nt and transgenic maize at the doses administered had 
no toxic effects on the mice (data not shown).  
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Discussion 
In this study we addressed the immunologic effects in mice of accidental consumption of low 
doses of maize transgenic for LT-B. The doses fed to the mice included 20 µg LT-B, a dose 
protective in vaccine studies, as well as five additional doses, with each 10-fold lower than 
the previous one (2, 0.2, 0.02, 0.002, and 0.0002 µg LT-B). The 20-µg dose was included in 
both experiments as a positive control. Chikwamba et al. (2002) and Mason et al. (1998) 
previously demonstrated that 10–50 µg LT-B fed 3 times intermittently to mice results in a 
protective level of antibody. Here we demonstrate that the 20-µg functional dose also results 
in a robust memory response that elicited 2-fold increases in serum IgG and 10-fold increases 
in serum and fecal IgA. Serum IgA represents a monomeric nonsecreted form of IgA. 
Although the biological function of serum IgA is unclear, differences in the concentration of 
serum IgA between animals correlates with differences in mucosally secreted IgA.  
 We have extended previous studies (Chikwamba et al. 2003; Karaman et al. 2006) by 
testing doses of 0.0002, 0.002, 0.02, 0.2, 2, and 20 µg LT-B for serum IgG and IgA as well 
as fecal IgA and we have observed a dose-dependent antibody response. Only mice that were 
fed ≥ 0.02 µg LT-B elicited significantly elevated levels of antibody. It should be noted that 
although the antibody response in the 0.02 µg group was low, it was significantly higher than 
that of the nt group in six of seven measures. The biological relevance of the low antibody 
concentration is underscored by the fact that approximately half the mice in the 0.02-µg 
group demonstrated a 4-fold increase in antibody when fed a 20-µg dose. No lower dose 
resulted in an antibody response or immune priming. From this study, we found that serum 
IgA was the most sensitive measure for detecting mice that had been immunologically 
primed. In addition, we identified 0.002 µg as the highest nonimmunostimulatory dose, one 
that resulted in neither an antibody response nor immune priming when fed intermittently.  
 Although we considered 0.02 µg LT-B a dose that results in immune priming, not all 
the mice in these groups resulted in a priming response. Some animals had fair antibody 
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responses while others appeared to have no response at all on days 54 or 55. One explanation 
for this is that there is some variability even between genetically inbred BALB/c mice that 
becomes obvious when feeding a dose that is borderline for inducing a response. 
Alternatively, the amount of LT-B in the maize fed to each mouse may not have been 
uniform. Our group has observed that the finer the transgenic maize kernels were ground, the 
more LT-B could be extracted and detected in ELISA (Chikwamba et al. 2002). Although the 
extra pellets that we prepared and assayed were all very close to containing 0.02 µg LT-B 
(0.0226, 0.0184, and 0.0195 µg), perfect homogenous mixes are not practical using ground 
maize and it is not inconceivable that one or more of the experimental pellets may have been 
more variable in LT-B content. This is more of a problem with borderline doses than with the 
high, immunogenic doses used as a functional vaccine.  
 Although there are many advantages to producing LT-B in maize, there are also 
concerns associated with genetically modified organisms (Schmidt 2005). Because of the 
high immunogenicity of LT-B, even at low levels, intermittent accidental consumption of 
maize transgenic for LT-B could result in an antibody response, immune priming, or both 
depending on the dose ingested. Whether immune priming has a positive or negative effect 
on future vaccine administrations has yet to be determined. We can hypothesize that it would 
boost the immune response to a future vaccination meant to protect animals or humans from 
the LT holotoxin; however, if LT-B were to be used as an adjuvant in a vaccine against a 
heterologous antigen, the response to that vaccine may be altered. Additionally, further 
research is needed to ensure that LT-B administered orally will not promote the development 
of tolerance to vaccines or allergies to co-administered food proteins.  
 This study provides data that are the first of their kind to begin assessing the 
consequences of accidental consumption of LT-B in maize. Risk assessment for 
noncancerous, nontoxic transgenic plants is evolving and includes the use of uncertainty 
factors to extrapolate from animals to humans (Kodell and Gaylor 1999). A recent risk 
   49
assessment by Wolt et al. (2006) of human exposure to LT-B in transgenic maize indicates 
that a dose 200-fold lower than a functional dose in humans is small enough to consider that 
maize unadulterated from a toxicologic perspective. However, in our mouse study, a dose 
1,000-fold lower than the functional 20-µg LT-B dose, 0.02 µg LT-B was immunogenic and 
caused immune priming in approximately half the mice. The highest nonimmunostimulatory 
dose tested was 10,000-fold lower than the functional 20-µg LT-B dose. Using this 
information, we can estimate a safe, nonimmunogenic dose for humans. Tacket et al. (2004) 
fed maize transgenic for LT-B to humans. The functional dose in this study was 1.1 mg LT-B 
per 70-kg adult. A dose 10,000-fold lower than this functional dose is equivalent to 0.11 µg 
LT-B, which is our best estimate for a nonimmunogenic dose in humans.  
 Consuming low immunostimulatory doses of LT-B does not result in adverse toxic 
effects, as indicated by no changes in animal body weight or overall health; however, the low 
dose may be enough to alter immune responses. An immune response to LT-B may not be 
harmful on its own, but if accidental consumption were to alter the way in which a person or 
animal would later respond to an oral vaccine containing LT-B in transgenic maize, it could 
render the vaccine less useful. For example, daily exposure to LT-B may induce oral 
tolerance. If accidental consumption of transgenic LT-B maize were to occur daily (as 
opposed to the intermittent feeding schedule used in this study), this could lead to vaccine 
inefficiency as well as a reduced ability of the immune system to eliminate an ETEC 
infection.  
 The data presented here apply to the intermittent feeding schedule used. We 
understand that mice exposed to the same doses of LT-B at differing intervals may have 
different immune responses. Further studies are needed to compare intermittent and 
continuous feeding regimens for transgenic maize. 
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Table 1.  Frequency of immune priming in mice fed 0.02 µg LT-B three times intermittently.  
_________________________________ _                                                                           
 Experiment 
Sample 1 2 Total___    
Serum IgG 2/4a 1/4 3/8 
 (50%)b (25%) (37.5%) 
 
Serum IgA 3/4 2/4 5/8 
 (75%) (50%) (62.5%) 
 
Fecal IgA 1/4 1/4 2/8 
 (25%) (25%) (25%) 
__________________________________                                                                 
aNumber of primed mice/total number of mice tested 
bPercentage of primed mice out of total mice tested 
 
Figure Legends 
Figure 1. Study #1 serum IgG concentrations in response to three intermittent feedings of 
LT-B (A) or a booster dose of 20 µg of LT-B given on day 49 (B). (A) LT-B feeding 
days are indicated by the arrows. Antibody concentrations are presented as mean ± SEM. 
(B) Group means are represented as bars (---). For both (A) and (B), n=4 mice per group, 
except for the non-transgenic group (nt) which had an n=8 on days -3 to 48.  
Figure 2. Study #1 serum IgA concentrations in response to three intermittent feedings of 
LT-B (A) or a booster dose of 20 µg of LT-B given on day 49 (B). (A) LT-B feeding 
days are indicated by the arrows. Antibody concentrations are presented as mean ± SEM. 
(B) Group means are represented as bars (---). For both (A) and (B), n=4 mice per group, 
except for the non-transgenic group (nt) which had an n=8 on days -3 to 48. 
Figure 3. Study #1 fecal IgA concentrations in response to three intermittent feedings of LT-
B (A) or a booster dose of 20 µg of LT-B given on day 49 (B). (A) LT-B feeding days are 
indicated by the arrows. Antibody concentrations are presented as mean ± SEM. (B) 
Group means are represented by bars (---). For both (A) and (B), n=4 mice per group, 
except for the non-transgenic group (nt) which had an n=8 on days -3 to 48.  
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Figure 4. Study #2 serum IgG concentrations in response to three intermittent feedings of 
LT-B (A) or a booster dose of 20 µg of LT-B given on day 49 (B). (A) LT-B feeding 
days are indicated by the arrows. Antibody concentrations are presented as mean ± SEM. 
(B) Group means are represented by bars (---). For both (A) and (B), n=4 mice per group, 
except for the non-transgenic group (nt) which had an n=8 on days -3 to 48.  
Figure 5. Study #2 serum IgA concentrations in response to three intermittent feedings of 
LT-B (A) or a booster dose of 20 µg of LT-B given on day 49 (B). (A) LT-B feeding 
days are indicated by the arrows. Antibody concentrations are presented as mean ± SEM. 
(B) Group means are represented by bars (---). For both (A) and (B), n=4 mice per group, 
except for the non-transgenic group (nt) which had an n=8 on days -3 to 48.  
Figure 6. Study #2 fecal IgA concentrations in response to three intermittent feedings of LT-
B (A) or a booster dose of 20 µg of LT-B given on day 49 (B). (A) LT-B feeding days are 
indicated by the arrows. Antibody concentrations are presented as mean ± SEM. (B) 
Group means are represented by bars (---). For both (A) and (B), n=4 mice per group, 
except for the non-transgenic group (nt) which had an n=8 on days -3 to 48.  
Figure 7. Study #2 lung lavage IgA concentrations on day 54 in response to a booster dose of 
20 µg LT-B given on day 49. Antibody concentrations are presented as mean ± SEM 
with n=4 mice per group. The groups are labeled according to the amount of transgenic 
maize fed on days 0, 7 and 21 in µg. The group nt + 20 is the non-transgenic group fed 20 
µg on day 49. The group nt is the non-transgenic group fed all non-transgenic maize. The 
group neg ctrl is the negative control group never handled, fasted or fed maize. 
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 Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Figure 7. 
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Abstract 
Transgenic maize expressing the non-toxic B subunit of the Escherichia coli heat-labile toxin 
(LT-B) in seed has proven to be an effective oral immunogen in mice.  Currently, there is 
considerable concern over accidental consumption of transgenic maize expressing LT-B by 
humans and domestic animals.  While consuming maize-expressed LT-B appears to have no 
toxic side effects, we have yet to determine if accidental exposure to LT-B could affect a 
later response to a vaccine containing LT-B as either an antigen or a carrier.  
 Our goal was to determine whether previous exposure to LT-B in maize, either daily 
or intermittent, would affect the immune response to oral vaccine-like boosters of LT-B in 
maize.  We fed mice intermittently (days 0, 7 and 21) with maize pellets containing 0.2 – 20 
µg LT-B per dose, or daily for 28 days with transgenic maize incorporated into their diet for 
daily consumption of 0.2 – 20 µg LT-B to resemble two distinct inadvertent exposure 
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scenarios.  We then boosted both treatment groups with high, vaccine-level transgenic maize 
pellets (20 µg LT-B per dose) on days 56 and 77.  Serum and fecal pellets were collected 
weekly to determine immune responses by measurement of LT-B-specific antibodies. 
 We observed dose-dependent antibody responses to the priming doses that were 
similar in both treatment groups.  In addition, all animals that had been previously exposed to 
LT-B by both intermittent and daily feeding responded strongly to the vaccine-like oral 
booster doses.  Mice that were exposed to maize-derived LT-B, whether daily or 
intermittently, generated dose-dependent antibody responses to LT-B.  When these primed 
mice were subsequently boosted with a vaccine dose of LT-B, strong LT-B-specific 
antibodies were detected.  This result indicates that mice frequently exposed to LT-B do not 
develop oral tolerance to LT-B, implying that inadvertent exposure to LT-B should not 
negatively impact future vaccinations containing LT-B as either an antigen or carrier. 
 
Introduction 
Recently, expression of vaccine antigens in plants has been explored as an approach to 
facilitate oral vaccination (10, 12, 18, 21). Unlike the parenteral route, oral delivery of 
vaccine antigens is able to elicit both a serum IgG and a secretory IgA response, the latter 
being essential for protecting the location by which most pathogens enter: mucosal surfaces. 
Plant delivery of vaccine antigens has many important advantages including economical 
production, safe delivery, and low risk of carrying mammalian pathogens (11, 17). 
 Our work focuses on transgenic maize expressing the B subunit of the Escherichia 
coli heat-labile toxin (LT-B). Previous studies have shown that this transgenic maize is both 
immunogenic and partially protective in a mouse model (2). Because of the natural 
encapsulation of the LT-B within the maize seed, maize-expressed LT-B is protected against 
harsh environmental conditions including high temperatures and enzyme degradation (3). 
This increased stability should lead to improved immunogenicity.  
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 The enhanced stability of maize-expressed LT-B is highly desirable for oral vaccine 
production, storage and effectiveness; however, it also poses a concern in the case of 
environmental contamination and/or accidental consumption by humans and domestic 
animals. Safety issues remain that must be addressed. The use of transgenic maize to produce 
a vaccine component opens the possibility for low dose antigen exposure of workers 
involved in its production or of consumers, should the product inadvertently occur in foods 
(23). 
 As opposed to the systemic immune system which responds to nearly all foreign 
antigens, the mucosal immune system is designed to selectively respond to foreign antigens 
(13). This makes food consumption an activity that generally does not result in an immune 
response. For example, repeated oral exposure to an egg protein such as ovalbumin will 
induce a state of immune non-responsiveness often referred to as oral tolerance (13, 22).  
However, unlike most protein antigens, LT-B is highly immunogenic when administered 
orally even at low doses (1).  Because of its immunogenicity, LT-B is not a typical protein 
and whether or not oral tolerance can be induced with daily exposure is still in question.  
While oral tolerance is typically tested by parenteral delivery following oral exposure, maize 
transgenic for LT-B was designed for an oral vaccine, therefore in this work we test for oral 
tolerance using oral exposure followed by oral boosters. 
   The possibility of inadvertent exposure to maize transgenic for LT-B leads to the 
question of whether previous inadvertent exposure will affect the ability of a person or 
animal to respond later to a vaccine containing LT-B either as an antigen or as a carrier. In 
this study, we address two potential exposure scenarios in mice, daily and intermittent 
exposure. We subsequently booster animals from these two exposure paradigms using a 
vaccine-like booster strategy in order to observe whether the earlier exposure affects the 
vaccine response.  Our results indicate that the immune system of mice responds to maize-
derived LT-B in a dose-dependent manner rather than a frequency-dependent manner.  In 
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addition, all mice responded strongly to the booster dose of LT-B whether they had been 
previously exposed daily or intermittently.   
 
Materials and Methods 
Preparation of maize pellets.  Production of maize transgenic for LT-B (4th generation 
transgenic seeds) and preparation of the maize seed pellets used as intermittent and booster 
doses were carried out as described previously with the following changes (1, 2). Briefly, the 
total weight of ground maize seed in each pellet was 0.767 grams and the ground seed was 
mixed with 550-600 µl of phosphate buffered saline (PBS) (1.9 mM NaH2PO4, 8.1 mM 
Na2HPO4, 0.15 M NaCl, pH 7.3). Two extra pellets were formed per dose for analysis and 
verification of LT-B content. Pellets of each type were refrigerated until ELISA analysis of 
LT-B content (four samples from each pellet).  
Preparation of transgenic and non-transgenic diet.  Mouse chow in powdered form was 
obtained from Harlan Teklad (Madison, WI, USA). For the mice that were fed LT-B daily, 
the diet was mixed with 0.237 grams transgenic (tg) and/or non-transgenic (nt) maize per 
gram of powdered custom diet specifically formulated to account for the maize added so that 
the final diet would closely resemble the Global Laboratory Rodent Diet® 2018 (2018 diet). 
A basal diet made from powdered Global Laboratory Rodent Diet® 2018 was used in 
feeding all mice during the acclimation period, the intermittently fed mice from days 0-28, 
and all mice from days 28-84. 
 To prepare the diets, the powdered components (diet with or without ground maize) 
were combined and mixed thoroughly before adding 70 ml nanopure water per 100 grams 
diet. The diet was mixed into dough and formed into a patty about 8 mm thick. The patty was 
scored, placed on a vented surface and allowed to dry for 24 hours. The patties were broken 
into ~4 cm squares along the scored lines, flipped over, and allowed to dry for an additional 
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24 hours. The diet squares were stored at 4°C until use.  Samples from extra tg and nt diets 
were assayed by ELISA for verification of LT-B content (eight samples per diet type).  
Oral immunization of mice.  Five-week-old female, BALB/c mice were obtained from 
Harlan Sprague Dawley, (Indianapolis, IN, USA) and were allowed a two week acclimation 
period prior to beginning the experiment with a 12-hour reversed light/dark cycle (lights on 
at 9 pm). The mice were housed one per cage in the Iowa State University (ISU) animal 
facility with food and water ad libitum. All procedures were approved by the ISU 
Institutional Animal Care and Use Committee.  
 Mice were divided into two main treatment groups:  daily feeding and intermittent 
feeding. Within each treatment, mice were divided into four groups of four mice based upon 
the dose of LT-B they were consuming either daily or intermittently (20, 2, 0.2 µg LT-B or nt 
maize).  
 Mice in the daily treatment consumed their appropriate dose of LT-B or nt diet daily 
for 28 days (days 0 – 28). During this time, mice in the intermittent treatment consumed 
basal diet and were given pellets of the proper dose on days 0, 7 and 21. After day 28, all 
mice were allowed a washout period and were only fed basal diet (contains no added tg or nt 
maize). This basal diet continued from day 28 to the end of the study. On days 56 and 77, all 
mice were given a booster dose in the form of a tg maize pellet containing 20 µg LT-B 
except for two of the nt mice from each treatment (daily and intermittent feeding). Mice 
previously in the nt group that were given 20 µg pellets on days 56 and 77 formed the nt + 20 
group. Mice not receiving 20 µg LT-B pellets received nt pellets (nt group) of equal weight.  
Prior to feeding maize seed pellets, the mouse chow was removed overnight (during the light 
phase). Mice were allowed to eat the pellet for 2-4 hours with water ad libitum. Upon 
completion of the pellet, the mice were returned to clean cages with mouse chow and water 
ad libitum.  
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 Analysis of extra pellets and diet indicated that the 2 and 0.2 µg LT-B pellets and diet 
contained amounts of LT-B very similar to the target amount.  For these groups, the target 
amount of LT-B fell within the 95% confidence interval of the sample measurements.  
However, for the 20 µg pellets and diet, the values measured were higher than anticipated 
and the target value fell outside the 95% confidence interval.  For the 20 µg pellets, the 
measured values ranged from 19.36 – 40.67 µg LT-B per pellet.  For the 20 µg daily diet, the 
target value was 6.175 µg LT-B/gram which would give about 20 µg LT-B per day with total 
food consumption of 3.239 g/day as determined prior to the feeding study and monitored 
during the study.  The measured values for this group ranged from 7.89 – 14.03 µg LT-
B/gram.  No LT-B was detected in either the nt pellets or commercially prepared diet (data 
not shown). Despite the differences in the target values and the measured values, this dose 
will be referred to as the nominal 20 µg dose and the groups receiving this dose will be 
referred to as the Intermittent and Daily 20 µg groups, respectively.  
Mouse weight and food consumption.  Mouse weights were collected before as well as 
weekly throughout the study in order to determine the effects of fasting and tg maize 
consumption on general health of the animals.  In addition, food consumption was measured 
at weekly intervals from day 0 – 28.  This data was used to confirm the total amount of LT-B 
that was consumed by mice fed LT-B daily. 
Sample collection, preparation and mouse euthanization.  Blood samples and fecal pellets 
were collected before the initial dosing as well as weekly throughout the study.  Serum and 
fecal pellets were prepared and stored and fecal pellets were extracted as described 
previously (1). Mice were euthanized with CO2 on day 84 with subsequent lung lavages 
performed at necropsy as described previously (1). 
Quantification of LT-B and LT-B-specific IgG and IgA.  ELISAs for the quantification of 
LT-B and LT-B-specific IgG and IgA were performed as previously described (1, 2, 8).  
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Quantification of LT-B-specific IgG1 and IgG2a.  Measurements of LT-B-specific IgG1 
and IgG2a in serum samples were carried out in a similar manner as measurements of LT-B-
specific IgG and IgA (described above) with modifications.  Briefly, LT-B-specific 
antibodies were detected using biotin-conjugated rat anti-mouse IgG1 (diluted 1:2000; BD 
Biosciences Pharmingen, Franklin Lakes, NJ, USA) or biotin-conjugated rat anti-mouse 
IgG2a (diluted 1:500; BD Biosciences Pharmingen).  Sample concentrations were 
determined by comparing to a standard curve consisting of wells coated with either purified 
mouse IgG1 (MOPC 21, Sigma, St. Louis, MO, USA) with a range of 0.78 – 100 ng/ml or 
IgG2a (UPC 10, Sigma) with a range of 1.95-250 ng/ml. 
Statistical analysis.  We analyzed antibody and mouse weight data with general analysis of 
variance, using treatment (intermittent or daily feeding schedule), LT-B dose, and sample 
day as variables in the model. Each day that was significantly different (p < 0.05) from the 
pre-feed date was further analyzed by between group contrasts. All antibody data were log 
transformed prior to analysis to correct for unequal variance (9). We used non-log 
transformed data for graphs. Pearson’s correlation values were obtained by using raw data for 
determination of correlation between antibody data sets. Analyses were conducted using the 
statistical software Statistix 8 (Analytical Software, Tallahassee, Florida).  95% confidence 
intervals were calculated in order to confirm that the measured amounts of LT-B in the 
pellets and diets were within the expected range.  This method was also used to confirm that 
the actual amounts of diet consumed by mice fed LT-B approximated the intended amount. 
 
Results 
Effect of maize consumption on mouse weight and total food consumption.  Mouse 
weights were recorded before beginning the experiment as well as weekly throughout the 
experiment.  No differences were detected between treatments or doses of LT-B (data not 
shown).  In addition, fasting prior to feeding pellets did not affect mouse weight.  The 
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average mouse weight at the beginning of the study was 18.2 (± 0.17) g and at the end of the 
study was 20.8 (± 0.19) g. 
 Food consumption was recorded over the first five weeks of the experiment during 
the priming period as well as twice during the booster period.  No difference was detected 
between mice that had been fasted (intermittent groups) and those that had not (daily groups).  
When analyzing whether LT-B consumption affected total food consumption, no difference 
was detected between those that had been given tg maize and those that received only nt 
maize (data not shown).  This data supports the claim that ingesting maize transgenic for LT-
B had no negative effects on food consumption and growth of mice.   
 The daily diets were formulated so that the mice would consume the proper dose of 
LT-B if they ate 3.239 g/day.  All groups, except for the Daily 20 group consumed the 
expected amount of diet each day as indicated by the target value falling within the 95% 
confidence interval for the measured values for each group.  The Daily 20 group consumed 
less food than intended; however, because we found the diet for this group actually contained 
more LT-B than expected, all mice still consumed more than 20 µg LT-B/day with an actual 
range of 26.8 – 31.8 µg LT-B per day.  This amount was quite similar to the Intermittent 20 
µg pellets which on average contained 33.9 µg LT-B. 
Serum IgG.  From days -2 to 55 (the priming period), a dose-dependent antibody response 
was observed as evidenced by a significant linear effect of dose (p < 0.0001) (figure 1A).  
While there was a statistical difference between intermittent and daily treatments (p = 
0.0092), this difference was only observed on days 48 and 55 with all doses (20, 2 and 0.2 µg 
LT-B) either significantly or marginally higher for daily feeding than for intermittent feeding 
on these days (p ≤ 0.0899). From days 62-83 (the booster period; figure 1B), a dose-
dependent response based on the priming dose was observed (linear effect: p < 0.0001) 
although it is not as visually obvious because most groups responded strongly to the 20 µg 
LT-B booster doses despite the fact that they were primed with differing amounts of LT-B. In 
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general, animals fed lower doses of LT-B during the priming period demonstrated a greater 
fold increase in antibody level from day 55 – 83.   
 We further compared serum IgG concentrations between groups for days 34 and 83 
which were peak days for most groups following priming and boosting, respectively.  
Moreover, day 34 was not significantly different from days 41, 48 and 55. As seen in figure 
2A, on day 34 we found that groups fed similar doses of LT-B (ie. Intermittent 20 vs Daily 
20) were not significantly different from one another.  Another way to compare data is to 
compare responses for groups receiving similar total amounts of LT-B during the priming 
period. For example, the Intermittent 20 µg group received a total of 60 µg across three pellet 
feedings and the Daily 2 µg group received a total of 56 µg across 28 days of feedings. When 
we compare the groups fed similar total amounts of LT-B during the priming feedings, those 
fed a total dose of about 60 µg were not significantly different from each other, but those fed 
a total dose of about 6 µg were significantly different.  This may indicate that 2 µg LT-B 
daily was sufficient for a strong priming response; however, 0.2 µg daily resulted in only a 
weak priming response. On day 83, we found that any group previously primed with LT-B, 
either daily or intermittently, responded strongly (5- to 105-fold) to the two 20 µg LT-B 
boosters (figure 2B).  We define a strong response as a ≥ 5-fold increase in antibody 
concentration from day 55 to day 83 for IgG and IgA. There was no difference between 
groups fed similar doses but with different feeding treatments (ie. Intermittent 20 vs. Daily 
20), or between groups fed similar total amounts of LT-B during the priming period. 
Although the Daily 0.2 µg group did not respond as strongly to boosting as the other groups, 
it was not significantly different from most groups fed LT-B during priming and serum IgG 
increased over 17-fold from day 55 to day 83.  
Serum IgA.  A dose-dependent response was observed with the priming data set for serum 
IgA concentrations induced by LT-B as indicated by a significant linear effect in dose (p < 
0.0001) as shown in figure 3A.  Over time there was no difference between the intermittent 
   70
and daily treatments. A dose response was observed for the booster data set based upon the 
priming dose as indicated by a significant linear effect (p < 0.0001) (figure 3B). 
 We further compared differences between groups on days 27 and 83. Day 27 was 
significantly different from days 34 – 55; however, as it demonstrated peak antibody levels 
for all groups, we chose to analyze this data set. Day 83, although not the peak day, 
demonstrated the same group comparison trends as the peak day (day 62), and also 
demonstrated the level of antibody in all groups following two booster doses. As seen in 
figure 4A, for day 27 serum IgA, groups fed similar doses of LT-B whether daily or 
intermittently were not significantly different from one another.  However, groups fed similar 
total amounts of LT-B (60 and 56 or 6 and 5.6 µg LT-B) during the priming feedings were 
significantly different from each other on day 27 indicating that intermittent feeding of larger 
doses is better able to stimulate an IgA antibody response than small doses daily. On day 83, 
we found that any group previously primed with LT-B, either daily or intermittently, 
responded strongly (~8- to 34-fold increase from day 55-83) to the 20 µg LT-B boosters 
(figure 4B).  While antibody concentrations were much higher on day 62 than any other day, 
this is due in part to the short half-life of IgA.  By day 83, there was no difference between 
groups fed similar doses whether daily or intermittently, or between groups fed similar total 
amounts of LT-B during the priming period. Despite the weaker response of the Daily 0.2 µg 
group, it was not significantly different from the Intermittent 2 and 0.2 µg groups and it 
demonstrated a nearly 17-fold increase from day 55 to day 83. Additionally, the nt + 20 
group clearly responded to the 20 µg booster as demonstrated by the high levels of antibody 
by day 83. The nt + 20 group on day 83 (four weeks after the first exposure to LT-B) had 1.5 
µg/ml serum IgA which was similar to the highest concentrations obtained by the daily and 
intermittent groups on day 27 (Daily 20 µg group = 1.3 µg/ml serum IgA; Intermittent 20 µg 
group = 1.4 µg/ml serum IgA). 
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Fecal IgA.  Because of the high rate of antibody breakdown in feces, a dose-dependent 
response to LT-B was not as obvious as in the serum antibody measurements; however, a 
dose-dependent response was present in the priming data set as evidenced by a significant 
linear effect (p < 0.0001) as shown in figure 5A.  Over time there was no significant 
difference between intermittent and daily treatments. A dose-dependent response was 
observed (p < 0.0001) for fecal IgA in the booster data set based upon the priming dose of 
LT-B although it was not visually obvious as most mice responded strongly to the booster 
doses despite being primed with different doses of LT-B (figure 5B).   
 We further compared groups on days 48 and 83. Day 48 was significantly different 
from days 27-41 and 55; however, it demonstrated peak antibody levels for most groups. As 
seen in figure 6A, on day 48 we found that groups fed similar doses of LT-B whether daily or 
intermittently were not significantly different from one another.  However, we had mixed 
results when comparing groups that were primed with similar total amounts of LT-B.  
Groups fed a total amount of about 60 µg LT-B were significantly different from one 
another, suggesting that intermittent feeding is the most efficient means of immunizing.  
However, the groups fed a total amount of about 6 µg LT-B were not significantly different 
from one another with both groups demonstrating relatively weak responses. On day 83, we 
found that any group previously primed with LT-B, either daily or intermittently, responded 
strongly (~7- to 35-fold increase from day 55 – 88) to the 20 µg LT-B boosters (figure 6B).  
By day 83, there was no significant difference between groups fed similar doses during 
priming whether daily or intermittently, or between groups fed similar total amounts of LT-B 
during the priming period. Additionally, the nt + 20 group was clearly responding to the 20 
µg boosters as demonstrated by the high levels of antibody (mean 0.7 µg/gram) by day 83. 
Lung lavage IgA.  Upon euthanization, lung lavages were performed to measure LT-B-
specific IgA in the lungs.  As shown in figure 7, all groups receiving LT-B either daily or 
intermittently during priming demonstrated significantly higher levels of LT-B-specific IgA 
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than the nt control group (p ≤ 0.0161) except for the Intermittent 0.2 µg group which was 
only marginally higher than the nt group (p = 0.0658).  While the nt + 20 group was not 
significantly higher than the nt group, the nt + 20 data did demonstrate elevated levels of IgA 
that were not significantly different from either of the 0.2 µg groups. There were no 
differences between groups fed similar doses but different treatments, or between groups fed 
similar total amounts of LT-B during the priming period. 
Correlation of data.  Serum IgG and serum, fecal, and lung lavage IgA measurements from 
day 83/84 were analyzed for correlation between data sets.  We found that serum IgG levels 
did not correlate with any of the IgA data sets; however, all three of the IgA data sets were 
significantly correlated (p ≤ 0.0001), with the highest correlation found between serum and 
fecal IgA. 
IgG1:IgG2a ratios.  To determine whether oral administration of maize transgenic for LT-B 
will lead to a Th1-or a Th2-type antibody response, LT-B-specific IgG1 and IgG2a were 
measured in serum samples from days 34 and 83.  Ratios of IgG1:IgG2a > 1 are considered 
indicative of a Th2-type response, while ratios < 1 are considered indicative of a Th1-type 
response (5).  On both days, all mice that received LT-B, either daily or intermittently 
demonstrated the presence of a strong Th2 response as indicated by high levels of IgG1 in 
comparison to IgG2a levels (Table 1). 
 
Discussion 
In this study, we address the immunologic effects of inadvertent exposure to maize 
transgenic for LT-B using laboratory mice as a model. Mice were given two exposure 
scenarios:  daily and intermittent.  We then administered LT-B to these animals in a vaccine-
like fashion to determine the effects of the daily and intermittent exposure on a future 
vaccine response. We found that both intermittent and daily exposures to maize transgenic 
for LT-B are able to elicit dose-dependent antibody responses with no consistent difference 
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between treatments.  Further, we found that animals previously exposed to LT-B, whether 
daily or intermittently, responded strongly to the booster doses given on days 56 and 77.  
This clearly indicates that daily exposure to LT-B does not induce immune non-
responsiveness commonly referred to as oral tolerance.  While daily exposure to LT-B 
induced strong antibody responses, especially in the 20 and 2 µg groups, it did not induce 
responses that were consistently higher than mice receiving intermittent doses of LT-B 
despite the fact that the daily fed mice were exposed to a total quantity of LT-B that was 
much higher than those fed the same dose intermittently.  Thus, clearly indicating that for an 
optimal vaccine antibody response, only a few well-spaced doses are necessary and more 
frequent administration would simply be a waste of product.   
 The data from the nt + 20 group provides another example of how dose spacing 
affects antibody responses.  This group received no LT-B until the 20 µg LT-B booster doses 
on days 56 and 77.  Unlike the Intermittent 20 µg group whose doses were spaced one and 
two weeks apart (days 0, 7 and 21), the nt + 20 group received only two doses three weeks 
apart.   Of interest is that four weeks after the I 20 and nt + 20 groups received their first 
dose, the serum IgG levels were quite different.  The Intermittent 20 µg group, after three 
doses, had a serum IgG level of 18.8 µg/ml as compared to the nt + 20 group which, after 
two doses, had a serum IgG level of 43.5 µg/ml which is more than 2-fold higher.  This 
suggests that increased spacing between doses enhances IgG responses. Interestingly, the 
serum and fecal IgA levels were not affected in the same way as serum IgG, as both groups 
demonstrated similar antibody levels. While it is possible that the age of the mice could have 
affected the resulting IgG response, it is not likely as the mice were only 8 weeks apart in age 
and all were adults at first exposure to LT-B. 
 While fecal IgA measurements for the priming data set (figure 5A) demonstrate a 
similar dose response for both treatments on days 34 – 55, the earlier days show more 
inconsistencies. This is especially true for the 20 µg groups where it appears as though daily 
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mice did not develop an antibody response until after the mice stop receiving daily doses of 
LT-B.  While this may be due to difficulty in measuring antibody concentrations in the feces 
due to antibody breakdown, we have been able to measure fecal IgA in intermittently fed 
mice and their fecal IgA correlates with serum IgA, thus we suspect that another problem 
may be that the LT-B that is in the gut at all times for daily fed mice may be binding the LT-
B-specific IgA.  Because our ELISA depends on the IgA binding to LT-B in the wells, any 
antibody already bound to LT-B would not be detected.  This would not have been a problem 
with mice fed intermittently since feedings were carried out one day after serum is collected 
and the LT-B should pass through the gut long before the next collection 6 days later. 
 During the booster period (shown in figures 1B, 3B, 5B), it is clear that the response 
to the first booster dose is much stronger than the response to the second booster dose for all 
measurements, but especially for serum IgA.  This strong response is indicated by a steeper 
slope from days 55 to 62 than from days 76 to 83.  While this may be partially due to 
previously present antibodies binding the LT-B from the second booster before it can bind to 
the gut and generate an immune response, it is more likely due to antibody-mediated 
feedback regulation (see Hjelm et al. (7) for a recent review).  Because higher levels of 
antibodies are present on day 77, the antibodies compete with LT-B-specific B cells and 
prevent clonal expansion (5).  It is possible that if we had given the second booster after 
antibody levels had waned, we may have seen a more robust response to the second booster. 
 Our findings concerning IgA at multiple locations also demonstrate the potential of 
LT-B in preventing or alleviating disease. First, the correlation of serum, fecal and lung IgA 
data sets demonstrates the range of the common mucosal immune system and emphasizes the 
potential of oral immunization with LT-B as a carrier.  Not only could oral immunization 
protect against gastrointestinal pathogens, but also respiratory pathogens as indicated by the 
presence of specific IgA in the lung.  Because the mice consumed the LT-B willingly and 
were not gavaged, it is unlikely that the IgA in the lung is due to aspiration.  While vaginal 
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IgA was not measured, the common mucosal immune system may make it possible to orally 
induce IgA in the vagina to protect against sexually transmitted diseases (19). Another way 
in which LT-B may be therapeutic is by modulating T helper cell responses. Our data 
demonstrating high IgG1 and low IgG2a levels supports previous findings that orally 
administered LT-B leads to a Th2 response (4, 15, 16). Th1 responses are generally pro-
inflammatory while Th2 responses tend towards anti-inflammatory (6, 14).  This would make 
LT-B a good candidate to serve as a carrier in therapies for diseases in which the 
inflammatory process is the primary cause of disease such as type I diabetes, multiple 
sclerosis and rheumatoid arthritis (6, 16, 20).  LT-B conjugated to a target antigen could 
potentially direct or shift the response towards anti-inflammatory in order to prevent or 
relieve disease symptoms.  One downfall to this Th2 response is that it also leaves the 
potential for development of allergies to linked proteins as Th2 cytokines can induce class-
switching to IgE in some ill-defined situations (14).  Further studies of LT-B, conjugated or 
unconjugated, are necessary to determine whether LT-B as a carrier for other antigens is both 
safe and therapeutic. 
 The data presented here show that consumption of maize transgenic for LT-B does 
not result in adverse toxic effects as confirmed by no changes in animal body weight or 
overall health.  In addition, we found that inadvertent daily exposure is not likely to 
negatively impact the immune response to a vaccine or therapeutic agent that may contain 
LT-B.  While further safety studies are needed to ensure that consumption of LT-B is not 
likely to induce allergies to co-administered food antigens, observations thus far indicate that 
consumption of LT-B is safe.   
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Table 1.  Serum IgG1:IgG2a Ratios 
0.70.04c0.03nt
an = at least 3-4 except where noted
bn= 2 due to lack of sample after running other ELISAs
cn=1 due to lack of sample after running other ELISAs
dIntermittent and daily nt groups combined for day 34, n= 5-7 due 
to lack of sample after running other ELISAs
319.00.0411.6aI 20
73.80.107.5I 2
38.30.02c0.9I 0.2
256.00.0819.7D 20
226.90.049.7D 2 
4.00.31b1.3D 0.2
0.80.010.01ntd
Day 83
157.10.4367.9I 20
47.61.0248.4I 2
31.41.8156.8I 0.2
28.02.0457.0D 20
520.80.1156.4D 2 
71.00.3021.6D 0.2
161.20.0914.8nt + 20
IgG1:IgG2a
IgG2a 
(µg/ml)
IgG1 
(µg/ml)Group
Day 34
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Figure Legends 
Figure 1. Serum IgG concentrations during the priming period (A) or the boosting period (B). 
(A) Arrows indicate feedings for intermittent LT-B groups and the bar represents the 
period during which daily LT-B groups were given diet containing LT-B ad libitum. (B) 
Arrows indicate 20 µg booster doses on days 56 and 77 given to all mice except the nt 
group. Group abbreviations consist of a letter indicating intermittent (I) or daily (D) 
feeding during priming and a number representing the dose of LT-B given in µg or nt 
representing the non-transgenic control group during the priming period. For (B), nt + 20 
represents a previously unprimed group that was administered 20 µg LT-B on days 56 & 
77. Antibody concentrations are presented as mean ± SE and n = 4 per group. 
Figure 2. Serum IgG concentrations on days 34 (A) and 83 (B).  Group abbreviations consist 
of a letter indicating intermittent (I) or daily (D) feeding during the priming period and a 
number representing the dose of LT-B given in µg or nt representing the non-transgenic 
control group. For (B), nt + 20 represents the previously unprimed group that was 
administered 20 µg LT-B on days 56 & 77. Total LT-B refers to the total amount of LT-
B the mice were exposed to during the priming period in µg.  Groups significantly 
different from one another are indicated by different letters beneath each group. Antibody 
concentrations are presented as mean ± SE and n = 4 per group. 
Figure 3. Serum IgA concentrations during the priming period (A) or the boosting period (B). 
(A) Arrows indicate feedings for intermittent LT-B groups and the bar represents the 
period during which daily LT-B groups were given diet containing LT-B ad libitum. (B) 
Arrows indicate 20 µg booster doses on days 56 and 77 given to all mice except the nt 
group. Group abbreviations consist of a letter indicating intermittent (I) or daily (D) 
feeding during priming and a number representing the dose of LT-B given in µg or nt 
representing the non-transgenic control group during the priming period. For (B), nt + 20 
   81
represents a previously unprimed group that was administered 20 µg LT-B on days 56 & 
77. Antibody concentrations are presented as mean ± SE and n = 4 per group. 
Figure 4. Serum IgA concentrations on days 27 (A) and 83 (B).  Group abbreviations consist 
of a letter indicating intermittent (I) or daily (D) feeding during the priming period and a 
number representing the dose of LT-B given in µg or nt representing the non-transgenic 
control group. For (B), nt + 20 represents the previously unprimed group that was 
administered 20 µg LT-B on days 56 & 77. Total LT-B refers to the total amount of LT-
B the mice were exposed to during the priming period in µg.  Groups significantly 
different from one another are indicated by different letters beneath each group. Antibody 
concentrations are presented as mean ± SE and n = 4 per group. 
Figure 5. Fecal IgA concentrations during the priming period (A) or the boosting period (B). 
(A) Arrows indicate feedings for intermittent LT-B groups and the bar represents the 
period during which daily LT-B groups were given diet containing LT-B ad libitum. (B) 
Arrows indicate 20 µg booster doses on days 56 and 77 given to all mice except the nt 
group. Group abbreviations consist of a letter indicating intermittent (I) or daily (D) 
feeding during priming and a number representing the dose of LT-B given in µg or nt 
representing the non-transgenic control group during the priming period. For (B), nt + 20 
represents a previously unprimed group that was administered 20 µg LT-B on days 56 & 
77. Antibody concentrations are presented as mean ± SE and n = 4 per group. 
Figure 6. Fecal IgA concentrations on days 48 (A) and 83 (B).  Group abbreviations consist 
of a letter indicating intermittent (I) or daily (D) feeding during the priming period and a 
number representing the dose of LT-B given in µg or nt representing the non-transgenic 
control group. For (B), nt + 20 represents the previously unprimed group that was 
administered 20 µg LT-B on days 56 & 77. Total LT-B refers to the total amount of LT-
B the mice were exposed to during the priming period in µg.  Groups significantly 
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different from one another are indicated by different letters beneath each group. Antibody 
concentrations are presented as mean ± SE and n = 4 per group. 
Figure 7. Lung lavage IgA concentrations on day 84. Group abbreviations consist of a letter 
indicating intermittent (I) or daily (D) feeding during the priming period and a number 
representing the dose of LT-B given in µg. The nt + 20 group represents a previously 
unprimed group that was boosted with 20 µg and the nt group represents the non-
transgenic control group. Total LT-B refers to the total amount of LT-B the mice were 
exposed to during the priming period in µg.  Groups significantly different from one 
another are indicated by different letters beneath each group. Antibody concentrations are 
presented as mean ± SE with n = 4 per group. 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Chapter 4.  Discussion 
 
 Maize-expressed LT-B has much potential for use in oral vaccines, whether as an 
antigen or as a carrier due to its high oral immunogenicity (Fingerut et al. 2006; Guidry et al. 
1997).  However, because the use of plants as production and delivery systems for oral 
vaccines is a relatively new area of research, many questions concerning the efficacy and 
safety of these vaccines remain to be addressed (Wolt et al. 2006).  We attempted to 
determine baseline safety information for use in future safety studies of LT-B as an oral 
vaccine component. 
 In the first study, we set out to determine at what level LT-B is nonimmunogenic 
when ingested.  This was to identify the immunological consequences of inadvertent 
exposure to LT-B in maize should it escape confinement, assuming that immunogenicity is 
one of the most sensitive measures of whether an ingested protein has an effect on the body.  
We found that LT-B in maize results in dose-dependent antibody responses upon oral 
administration.  In addition, we found that 0.02 µg LT-B, when consumed three times 
intermittently, results in immune priming even though it does not elicit measurable antibody 
responses.  This indicates that consuming low doses of LT-B may result in immunological or 
other outcomes that are not detectable, even with highly sensitive assays.  Furthermore, we 
found that 0.002 µg LT-B was the highest dose tested that did not result in a measurable 
antibody response or immune priming.  The fact that LT-B is immunogenic in mice at levels 
as low as 0.02 µg, a dose 1000-fold lower than a vaccine dose, underscores the extraordinary 
immunogenic potential of LT-B for use as a vaccine component. 
 The second study evaluated the immunological effects of intermittent and daily 
administration of LT-B in maize in order to resemble periodic or near continuous inadvertent 
exposure to LT-B.  We found that antibody responses were LT-B dose-dependent more so 
than frequency-dependent with mice fed similar doses but at differing intervals generating 
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very similar antibody responses.  In addition, all mice, whether primed intermittently or 
daily, responded strongly to the subsequent booster doses of LT-B.  Because mice previously 
fed daily responded as strongly to the booster doses as mice previously fed intermittently, 
and daily oral exposure elicited LT-B-specific serum IgG, we can conclude that daily 
exposure to LT-B does not result in oral tolerance.  The ability of LT- B to avoid oral 
tolerance induction, even when administered at low doses daily, demonstrates its outstanding 
potential as an oral vaccine component. 
 Together, these two studies begin to assess the immunologic effects of oral exposure 
to transgenic maize expressing LT-B.  Wolt et al. (2006) suggest that two primary categories 
that must be addressed in regard to safety evaluation of plant-derived pharmaceuticals are 
exposure and hazard assessment.  Our first study addresses exposure assessment by 
identifying a level at which oral exposure should not have an effect on the body.  Both 
studies address hazard assessment in regard to measurement of mouse weights throughout the 
study and finding no difference between mice orally administered LT-B and those 
administered non-transgenic maize.  The second study further evaluates the hazard of 
inadvertent exposure in a practical use setting by assessing whether previous exposure would 
have a negative impact on a vaccine response.  Taken together, the results from these two 
studies indicate that oral exposure to LT-B in transgenic maize is not hazardous. 
 Safety issues that remain to be addressed for maize-expressed LT-B include 
allergenicity studies.  No indication of allergy development due to oral exposure to LT-B in 
maize has been reported in previous studies (as reviewed by Wolt et al. 2006) or observed in 
our animal studies; however, because we found that LT-B induces antibody responses that 
are strongly Th2 biased, the potential for allergy development exists (Moss et al. 2004).  
These studies should first evaluate whether allergy to LT-B develops.  Subsequent studies 
focusing on the development of allergies to conjugated or co-administered protein antigens 
would also be beneficial.  This would indicate whether using LT-B as an adjuvant or carrier 
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is likely to induce allergy to the antigen of interest.  It would also be beneficial to examine 
whether LT-B in transgenic maize elicits an allergenic response to maize proteins which 
would cause food allergy.  
 LT-B as a model antigen for safety evaluation of pharmaceutical products produced 
in plants is an extreme example due to its high immunogenicity (Fingerut et al. 2006; Guidry 
et al. 1997).  Most other proteins administered orally will likely not result in strong immune 
responses as those demonstrated by LT-B.  However, LT-B is a good model antigen because 
it demonstrates the furthest extent to which a vaccine component is likely to be orally 
immunogenic and provides a baseline for further safety evaluation of LT-B, whether as a 
vaccine antigen or carrier, and other plant-produced vaccine antigens. 
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